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Während der Tumorentwicklung führen eine Vielzahl an Mechanismen zur verstärkten 
Immunsuppression. Hierzu gehören Veränderungen in der Myelogenese, die zur Anreicherung 
und Rekrutierung von Suppressionszellen führen, auch bezeichnet als „Myeloide 
Suppressionszellen“ (MDSC = myeloid-derived suppressor cells). Ursprünglich wurden MDSCs in 
Tumorpatienten und Tumor-tragenden Mäusen als Zellen beschrieben, die in der Lage sind  
T-Zellantworten zu unterdrücken. Während der Tumorentwicklung akkumulieren MDSCs im 
Knochenmark, Blut, peripheren Lymphorganen und im Tumorgewebe. Sie bilden eine heterogene 
Gruppe aus myeloiden Zellen, die sich in verschiedenen Entwicklungsstadien befinden. Maus 
MDSCs sind durch ihre Koexpression der Oberflächenmoleküle Gr-1 und CD11b charakterisiert, 
die anhand ihrer morphologischen Unterschiede in zwei Untergruppen gegliedert werden. 
Während die mononukleären Zellen (MO-MDSC) die Marker Ly6C und F4/80 exprimieren, 
zeichnet sich die polymorphnukleäre Subpopulation (PMN-MDSC) durch eine 
Oberflächenexpression von Ly6G aus. Zusätzlich fehlt der PMN-MDSC Gruppe der 
Makrophagenmarker F4/80. 
Ziel unserer Studie war es, die Verteilung der einzelnen MDSC Subgruppen im Blut und Tumor zu 
analysieren, deren Transkriptionsprofil zu untersuchen und anhand unterschiedlich exprimierter 
Proteine die Funktion zu bestimmen. Unsere Untersuchungen zeigten, dass nach subkutaner 
Injektion von RMA-S Zellen beide MDSC Populationen in den Tumor einwanderten. 
Genexpressionsanalysen mittels Microarray ließen deutliche Veränderungen des 
Transkriptionsprofils zwischen den Untergruppen im Blut bzw. im Tumor erkennen. Verglichen zu 
MDSCs aus dem Blut, zeigten Tumor-infiltrierende MO-MDSCs eine erhöhte Expression von 
Genen, die eine wichtige Rolle in Immunsuppression, Entzündungsantworten und Chemotaxis 
spielen. Die meisten dieser Genveränderungen auf Transkriptionsebene konnten ebenso auf 
Proteinebene bestätigt werden. Tumor-infiltrierende MDSCs wiesen eine erhöhte 
Oberflächenexpression von TLR-4, CD14, und Dectin-2 auf, was auf einen pro-inflammatorischen 
Phänotyp im Tumorgewebe rückschließen lässt. Stimulierung des CD14/TLR-4 Komplexes mit LPS 
führte zu einer erhöhten Expression des NKG2D Liganden, Rae-1, wodurch Natürlichen Killerzellen 
besser aktiviert werden könnten. 
MO-MDSCs im Tumor zeigten eine erhöhte Aktivität von hemmenden Enzymen wie Arginase-1 
bzw. iNOS verglichen zu MDSCs aus dem Blut. Zudem beobachteten wir, dass nur Tumor-
infiltrierende MO-MDSCs hohe Mengen an Chemokinen produzierten. Dazu gehören drei 
Liganden des Chemokinrezeptors CCR5: CCL3 (MIP-1α), CCL4 (MIP-1β) und CCL5 (RANTES). 
Wiederholte Injektionen dieser rekombinanten Chemokine in den Tumor führten zur verstärkten 
Anreicherung von regulatorischen T-Zellen (Treg) bzw. zu einem verminderten Verhältnis von 
CD8+/Tregs im Tumor. Zusätzlich wurde das Tumorwachstum beschleunigt und die 
Überlebensrate der Mäuse verringert. Im Gegensatz dazu zeigten CCR5 defiziente Mäuse, die mit 
RMA-S Tumorzellen injiziert wurden, ein vermindertes Tumorwachstum und eine verlängerte 
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Überlebensrate, was mit einer erhöhten Zellzahl an CD4+ und CD8+ T-Zellen und einem Anstieg der 
CD8+/Treg Ratio im Tumor korrelierte.  
Zusammenfassend zeigen unsere Daten, dass Tumor-infiltrierende MO-MDSCs eine 
unterstützende Rolle in der Tumorentwicklung übernehmen. Die erhöhte enzymatische Aktivität 
von Suppressionsfaktoren kann T-Zellantworten auf direktem Weg vermindern, während 
sezernierte Chemokine der Tumor-infiltrierenden MO-MDSCs indirekt das Immunsystem durch 
Anreicherung von Tregs im Tumor schwächt. Diese Ergebnisse beschreiben eine neue 
regulatorische Funktion der MDSCs in der Rekrutierung von Tregs, wodurch Behandlungen zur 
effektiven Tumortherapie verbessert werden könnten.  
 





Several mechanisms have been proposed for profound immune impairments that accompany 
tumor development. Alteration in myelopoiesis that occur during tumor growth leads to the 
accumulation and recruitment of immunosuppressive cells, known as myeloid-suppressor cells 
(MDSCs). MDSCs have been characterized in cancer patients and tumor bearing mice based on 
their ability to suppress T cell responses. During tumor progression MDSCs accumulate in bone 
marrow, blood, peripheral lymphoid organs and in the tumor tissue. They represent a 
heterogeneous population of myeloid cells at different stages of differentiation. In mice these 
cells are characterized by the co-expression of the surface markers Gr-1 and CD11b. Within this 
population, two distinct MDSC subpopulations with clear morphological differences have been 
identified, comprising mononuclear cells (MO-MDSCs), which express Ly6C and the macrophage 
marker F4/80, and polymorphonuclear cells (PMN-MDSCs), which express Ly6G and do not display 
F4/80 surface expression.  
The aim of this thesis was to determine the distribution of tumor-infiltrating and blood MDSC 
subsets as well as the molecular signature and function of genes differently regulated in MDSC 
subpopulations. We demonstrated that after subcutaneous injection of RMA-S tumor cells, both 
MDSC subsets accumulated in the tumor tissue. Gene expression profiling of blood and tumor-
infiltrating MDSCs using whole genome microarrays revealed profound changes in the 
transcription profile between MDSC subsets in blood and tumor. Tumor-infiltrated MO-MDSCs 
displayed increased expression of genes involved in suppression, inflammatory responses and 
chemotaxis compared to blood MDSCs. We confirmed that differentially regulated genes at mRNA 
level were also differently expressed at protein levels and might play a significant role in MDSC 
function. In addition, tumor-infiltrating MDSCs showed an increased surface expression of TLR-4, 
CD14, and Dectin-2, suggesting a pro-inflammatory phenotype of these subsets in the tumor 
tissue. Stimulation of the CD14/TLR-4 complex with LPS resulted in an upregulation of the NKG2D 
ligand Rae-1, which might be involved in natural killer cell activation. 
Compared to blood MDSCs, the activity of suppressive factors such as arginase-1 and iNOS was 
increased in tumor-infiltrating MO-MDSCs. In addition, we observed that only tumor-infiltrating 
MO-MDSCs expressed high amount of several chemokines including three ligands of the 
chemokine receptor CCR5: CCL3 (MIP-1α), CCL4 (MIP-1β) and CCL5 (RANTES). Intra-tumoral 
injection of these recombinant chemokines resulted in an increased accumulation of regulatory  
T cells and a lower CD8+/Treg ratio in the tumor tissue correlated with accelerated tumor growth 
and shortened survival of tumor-bearing mice. On the contrary, CCR5 deficient mice injected with 
RMA-S tumor cells showed reduced tumor growth and prolonged survival associated with high 
numbers of CD4+ and CD8+ T cells and an increased CD8+/Treg ratio detected in the tumor.  
In summary, we demonstrated that tumor-infiltrating MO-MDSCs exerted key features to 
promote tumor progression. Increased expression of suppressive factors by MO-MDSC in the 
tumor tissue might directly downmodulate T cell responses, whereas chemokine secretion might 
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induce the accumulation of tumor-infiltrating regulatory T cells, resulting in additive immune 
suppression. Those findings defined a new regulatory role of MDSCs in recruiting Tregs, which 
might be clinically relevant in developing novel immunotherapeutic strategies for cancer patients. 





3.1 The immune system 
 
The immune system represents a complex network of cells, tissues and organs that protects the 
host from foreign pathogens and tumors. The main function of the immune system is 
accomplished by the ability to recognize “non-self” and “altered-self” structures on infected or 
transformed cells. Molecules that can be recognized by the immune system are considered 
antigens. In vertebrates, the immune system is divided into two distinct components based on 
antigen specificity and kinetics of activation: the innate and the adaptive immunity. 
 
3.1.1 The innate immune system 
 
The innate immune system serves as the first line of host defence against pathogens and prevents 
the entrance and establishment of infectious agents. It is naturally present and does not require 
sensitization to antigens. The innate immune system is comprised of a variety of cells, including 
natural killer (NK) cells, monocytes/macrophages and dendritic cells (DCs) and several plasma 
proteins like the complement system.  
Once an infectious agent penetrates physical and chemical barriers (e.g. epithelia), pattern 
recognition receptors (PRRs) of the innate immune system sense their molecular structures so 
called pathogen associated molecular patterns (PAMPs). Bacterial PAMPs often include cell wall 
components such as lipopolysaccharides (LPS), peptidoglycan and lipoteichoic acids. Additionally, 
fungal molecules (β-glycans) as well as viral proteins or unmethylated CpG motifs in bacterial and 
viral nucleic acids can be recognized. The best characterized PRRs are the Toll-like receptors (TLR), 
whose activation leads to pathogen uptake by phagocytic cells (including macrophages, dendritic 
cells, neutrophils). Beside pathogen destruction, pro-inflammatory cytokines and chemokines are 
secreted resulting in recruitment and activation of other immune cells [1]. One of the most potent 
effector cells of the innate immune system are DCs. They reside as immature cells in the tissue. 
Pathogen detection and uptake lead to their maturation and secretion of factors that support 
innate immune responses. Once maturated, they migrate to the local lymph node, where they 
induce adaptive immune responses. Thus, DCs link the innate with the adaptive immune system 
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3.1.2 The adaptive immune system 
 
In contrast to innate immunity, the adaptive immune system shows delayed responses to 
pathogens. The two main cell populations of the adaptive immune system are T and  
B lymphocytes (T and B cells), which recognize a high diversity of antigens. Their receptors are 
random products of somatic gene rearrangement during maturation. The genes encoding these 
receptors are assembled from variable and constant fragments through the activity of enzymes 
called RAG-1 and RAG-2 (recombination activation gene) [2]. 
Defence against extracellular microbes and microbial toxin is mediated by B cells. They originate 
from bone marrow and their maturation is accompanied by the expression of membrane bound 
immunoglobulins, called B cell receptors (BCRs). Activation of B cells upon antigen encounter 
leads to their differentiation into either memory or antibody-secreting plasma cells. Antibodies 
are composed of different classes and therefore mediate a variety of specific responses including 
antigen neutralization, opsonization of pathogens or activation of the complement system.  
While extracellular pathogens are recognized by B cells, intracellular microorganisms are detected 
by T lymphocytes via cell-mediated immune responses. T cells also arise in the bone marrow but, 
unlike B cells, migrate to the thymus to complete their maturation. Their receptors, T cell 
receptors (TCRs), recognize antigens only when displayed as peptides bound to self major 
histocompatibility complex (MHC). Based on the class of MHC molecules they bind to, T cells are 
divided into CD4+ (bind to MHC class II) or CD8+ subsets (bind to MHC class I). To fully activate T 
cells, additional costimulatory signals are necessary, which are displayed by antigen-presenting 
cells (APCs). 
 
3.2 Tumor immunology 
 
The ability of the immune system to identify and destroy tumor cells has been studied for many 
decades. In 1909, Paul Ehrlich proposed that the immune system could protect the host from 
neoplastic disease. Nearly 50 years later the concept of cancer immunosurveillance was 
introduced by Burnet and Thomas. Based on the better understanding of tumor biology, they 
predicted that lymphocytes were responsible for the elimination of continuously arising 
transformed cells [3]. Data supporting this hypothesis are derived from several studies carried out 
with immunodeficient mice. Moreover, clinical data have led to a growing appreciation that 
cancer immunosurveillance also occurred in humans (reviewed in [4]). Later on, Schreiber and 
colleagues proposed a more sophisticated theory implicating that immunity not only protects the 
host from tumor development but also promotes tumor growth by generating more aggressive 
tumors. The term “cancer immunoediting” has been used to describe this dual host protective 
and tumor promoting mechanism [5], [6].  
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3.2.1 Hallmarks of cancer 
 
Cancers arise in a multistep process that reflects dysregulation of oncogenes, tumor suppression 
and pro-apoptotic signals. Genetic and epigenetic alterations lead to changes in cell growth, 
proliferation and differentiation and thus cause the development of tumors. As suggested by 
Hanahan and Weinberg, six essential alterations in cell physiology contribute to transform normal 
cells into malignant cancer cells: (a) self-sufficiency in growth signals, (b) insensitivity to anti-
growth signals, (c) limitless replicative potential, (d) evasion of apoptosis, (e) sustained 
angiogenesis and (f) tissue invasion and metastasis [7]. 
a) Self-sufficiency in growth signals. Normal cells are dependent on growth signals to move into a 
proliferative state. Many cancer cells acquire the ability to generate their own growth factors, 
thereby reducing their dependence on stimulation from their normal tissue microenvironment. 
This creates a positive feedback loop that is known as autocrine stimulation.  
b) Insensitivity to anti-growth signals. To maintain cellular quiescence and tissue homeostasis 
multiple anti-proliferative signals are established within a normal tissue. Such signals include 
soluble growth inhibitors like transforming growth factor-β (TGF-β), which prevents activation of 
transcriptions factors responsible for the cell cycle machinery. Many tumors disable components 
of the TGF-β-mediated signaling pathway to achieve insensitivity to those inhibitory signals.  
c) Limitless replicative potential. In addition to avoiding anti-growth signals and generating 
positive growth signals, tumor cells also escape the normal limits of cell replication. Most 
malignant cells upregulate the expression of the enzyme telomerase (e.g. the subunit TERT; 
telomerase reverse transcriptase), which adds nucleotides to the ends of DNA. This in turn 
permits unlimited multiplication of descendant cells.  
d) Evading apoptosis. Uncontrolled cell division can also be fueled by a cancer cell ability to evade 
programmed cell death (apoptosis). The apoptotic program can be carried out through two main 
pathways: surface receptors that bind survival or death factors (e.g. FAS receptor CD95), 
therefore monitoring the extracellular environment, and intracellular sensors that response to 
abnormalities including DNA damage. Tumors can develop resistance to apoptosis-inducing 
effector mechanisms mediated by these pathways. 
e) Sustained angiogenesis. The oxygen and nutrients supplied by the vasculature are crucial for 
cell function and survival. During tumor development incipient neoplasias display increased 
angiogenic ability in order to progress to a larger size. Secretion of augmented levels of the 
vascular endothelial growth factor (VEGF) to promote angiogenesis is one of the most common 
feature of tumor cells. 
f) Tissue invasion and metastasis. During tumor progression cancer cells escape the primary 
tumor mass and invade distant tissues. This invasion - metastasis - requires alterations of proteins 
involved in cell-cell adhesion (e.g. E-cadherin), as well as in the secretion of proteases like matrix 
metalloproteinases (MMPs) which degrade extracellular matrix proteins.  
Eva Schlecker  INTRODUCTION 
 
16 
In the late 90s, “immunoevasion” has been proposed as an additional hallmark of tumors. In order 
to progress, tumors have to evolve strategies for evading immune responses. These mechanisms 
include production of immunosuppressive cytokines, apoptosis of activated T cells or loss of 
costimulatory and HLA class I molecules [8]. 
 
3.2.2 Cancer immunoediting 
 
The concept of cancer immunoediting predicts that the immune system can recognize neoplastic 
cells. By eliminating high immunogenic tumor cells, new tumor cell variants with reduced 
immunogenicity may be selected and therefore favor the generation of tumors that show 
increased resistance to immune attack or that have acquired mechanisms that suppress immune 
effector functions. Taken together, cancer immunoediting comprises a dynamic process 
composed of three phases: elimination, equilibrium and escape (Figure 3.1). Elimination 
represents the classical concept of cancer immunosurveillance where immune cells fight arising 
tumors; equilibrium embodies the stage of immune-mediated latency after incomplete tumor 
destruction and escape refers to the final outgrowth of immune resistant tumors that are 
resistant to the immune system. 
 
 
Figure 3.1: The three phases of the cancer immunoediting process 
A variety of oncogenic stimuli transform normal cells into tumor cells (top). At early stages these cancer cells 
express distinct tumor-specific markers and initiate pro-inflammatory responses (bottom). In the elimination 
phase innate and adaptive immune cells recognize and kill tumor cells. During equilibrium tumor cells persist but 
are prevented from expanding by the immune system. However, less immunogenic tumor cells survive and 
escape resulting in tumor outgrowth. (Dunn et al. Immunity 2004; 21: 137-148) 
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3.2.2.1 Elimination phase: Anti-tumor immune responses 
 
The elimination phase requires an integrated response involving both the innate and the adaptive 
arms of the immune system. Evidence was supported by tumors in mice lacking RAG-2, which 
cannot produce T cells, B cells and NKT cells. They develop tumors faster and with higher 
frequency than wild-type controls [9]. 
The initiation of the anti-tumor immune response occurs when cells of the innate immune system 
become alerted of the presence of the growing tumor. Local tissue disruption as a result of 
increased angiogenesis or tissue-invasive growth induces pro-inflammatory molecules (e.g. 
interleukin 1 (IL-1), tumor necrosis factor α (TNF-α), granulocyte-macrophage colony-stimulating 
factor (GM-CSF) or IL-15), leading to the recruitment of innate immune cells. Dendritic cells may 
act as sentinel cells sensing tissue stress, damage and transformation. Their ability to uptake heat 
shock proteins and products of extracellular matrix breakdown promotes differentiation and 
subsequent cross-talk between DCs and NK cells.  
NK cells, macrophages, γδ T cells and NKT cells are recruited to the site of “danger” and recognize 
molecules that can be induced on tumor cells upon cellular transformation, such as stress induced 
ligands for the activating receptor NKG2D [10]. In addition, MHC-tumor-associated peptide 
complexes or glycolipid-CD1 complexes expressed on developing tumor cells can be recognized by 
T cells and NKT cells, respectively [11]. These immune cells exert several effector mechanisms to 
eliminate tumor cells including the release of IFN-γ and perforin or the expression of death 
receptor ligands such as TRAIL. Secretion of IFN-γ controls tumor growth and amplifies immune 
responses through the production of chemokines. In return, chemokines attract more immune 
cells to the tumor site generating a positive feedback loop for tumor elimination.  
In the next phase tumor antigens released during tumor cell killing drive the development of 
tumor-specific adaptive immune responses. Recruited immature DCs become activated through 
the tumor cytokine milieu and uptake of tumor antigens and migrate to the lymph nodes, where 
they induce the activation of naïve tumor-specific CD4+ and CD8+ T cells [12]. Once activated, 
tumor-specific T cells home to the tumor site to eliminate antigen-expressing tumor cells.  
 
3.2.2.2 Equilibrium phase: Tumor persistence 
 
In the equilibrium phase immune cells and tumor cells which survived the elimination phase enter 
a dynamic process where new tumor variants with increased resistance to the immune attack 
arise. Schreiber and colleagues hypothesized that equilibrium may be the longest of the three 
phases and may occur over a period of many years in humans [13]. During this period 
heterogeneity and genetic instability of remaining cancer cells may favor the generation of 
tumors that are either poorly recognized by the immune system or that have acquired 
mechanisms that suppress immune effector functions.  
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3.2.2.3 Escape phase: Tumor progression 
 
In the escape phase, selective pressure of immune responses and further mutations in malignant 
cells lead to tumor progression. Most likely, tumors circumvent either one or both arms of the 
immune system by employing multiple immunoevasive strategies. Several studies documented 
that tumors can either directly (tumor intrinsic mechanism) or indirectly (tumor extrinsic 
mechanism) impede anti-tumor immune responses. Tumor intrinsic mechanisms include:  
(a) modified expression level of MHC class I/II and costimulatory molecules [14], (b) dysregulation 
of antigen processing [15] and (c) low levels of tumor antigen expression [16]. Indirect 
mechanisms are associated with: (a) tolerance of T cells to tumor-specific antigens resulting from 
anergy [17], (b) suppression of immune effector cells via immunosuppressive cytokines such as 
TGF-β or IL-10 [18] or via regulatory cells [19] and (c) secretion of soluble ligands that block 
lymphocyte activation [20]. 
 
3.3 Monocyte and macrophage heterogeneity 
 
Macrophages comprise an extremely heterogeneous population that originates from blood 
monocytes. They play an important role in the immune system with defined functions in both 
innate and adaptive immunity. In innate immunity they provide immediate defense against 
foreign pathogens through phagocytosis and subsequent degradation of apoptotic or possibly 
neoplastic cells. During the adaptive immune phase they interact with T and B cells by releasing 
cytokines, chemokines and reactive radicals. In cancer, macrophage activities can either prevent 
the establishment and spread of cancer (pro-inflammatory) or support tumor growth (anti-
inflammatory). These polar phenotypes are not expressed simultaneously but are regulated 
through decisive functional programs in response to different micro-environmental signals [21].  
 
3.3.1 Macrophage plasticity 
 
Macrophages can be divided schematically into two main classes. M1 macrophages are classically 
activated macrophages induced by microbial products like LPS or cytokines like IFN-γ, TNF and 
GM-CSF. Alternative activation of M2 macrophages is regulated by IL-4, IL-13, IL-10 or 
glucocorticoids [22].  
M1 and M2 polarized macrophages display a number of distinct features (Figure 3.2). Classical M1 
macrophages are characterized by a high capacity to present antigens, they produce elevated 
levels of IL-12 and IL-23 and therefore activate type I T cell responses. Due to their high 
production of toxic intermediates (nitric oxide, NO; reactive oxygen, intermediates ROI), M1 
macrophages are potent effector cells that kill tumor cells and microorganisms. When exposed to 
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signals such as LPS and IFN-γ, they express opsonic receptors like FcγRIII (CD16) and produce pro-
inflammatory cytokines in order to elicit adaptive immunity. 
Alternatively activated M2 macrophages possess poor antigen presenting capacity, have an  
IL-12lowIL-10high phenotype, secret CCL17 and CCL22, suppress inflammatory responses and Th1 
adaptive immunity, scavenge debris and promote wound healing, angiogenesis and tissue 
remodeling. They express surface markers like E-cadherin, CD163 and CD206 [23]. Instead of 
citrulline and NO production via iNOS as seen in M1 macrophages, the arginine metabolism of M2 
macrophages is oriented towards ornithine and polyamine production [24], [25].  
Mantovani and colleagues defined that various environmental signals further designate distinct 
M2 activation forms: M2a macrophages are activated by IL-4 and IL-13, M2b cells arise after 
exposure to immune complexes or agonists of TLR and IL-1R and M2c macrophages are 
predominantly induced by IL-10 [26]. 
Analogous to the M1/M2 paradigm, Geissmann et al. identified inflammatory and resident 
monocyte subsets. In mice, inflammatory monocytes exhibit a CX3CR1lowCCR2+Gr-1+ phenotype, 
are short-lived and recruited to inflamed tissue, whereas resident monocytes are characterized by 













3.3.2 Molecular pathways of macrophage polarization 
 
Macrophage phenotype and activation are regulated by three different pathways: (a) cytokine 
signaling pathway using Jak-STAT molecules, (b) microbial recognition receptors including TLRs 
and (c) immunoreceptors that signal via ITAM motifs (immunoreceptor tyrosine-based activation 
motif). M1 stimuli such as LPS and IFN-γ trigger TLR-4, IFN-α/β receptor or IFN-γ receptors. These 
signals result in activation of the transcription factors NFκB, AP-1, IRF3 and STAT1 and further to 
the transcription of M1 genes. In contrast, M2 stimuli such as IL-4/13, signal through IL-4Rα to 
activate STAT6, which regulates the expression of M2 genes. Immune complexes trigger the FcγR, 
an ITAM-containing receptor, leading to activation of kinases (e.g. Syk and PI3K) and the 
expression of molecules like prostaglandin E and IL-10 [28]. 
 
3.4 Tumor-associated macrophages 
 
Solid tumors are constituted of different cell types including neoplastic cells, fibroblasts, 
endothelial and immune-competent cells, the latter mainly consists of macrophages and 
lymphocytes. Macrophages infiltrating the tumor, so called tumor-associated macrophages 
(TAM), are usually the most abundant immune population in the tumor and represent up to 50% 
of the tumor mass [29]. 
Pollard and colleagues have been proposed that macrophages in tumors confer several properties 
that enhance progression and metastasis, where each function is affected by a particular 






Figure 3.2: Polarization of macrophage function 
Macrophages can be divided into two main classes: M1 and M2. Blood monocytes recruited from the circulation 
differentiate into mature macrophages within the tissue. In the presence of LPS/IFN-γ or GM-CSF polarization of M1 
macrophages is induced. M1 macrophages produce high levels of IL-1, TNF-α, IL-12, IL-23, CXCL10 and ROI. They are 
characterized by cytotoxic activity against bacteria and neoplastic cells and by the capability of antigen presentation. 
Cytokines like IL-4, IL-13, IL-10 or glucocorticoids drive the M2 polarization. M2 macrophages secrete high amounts of 
IL-1ra, IL-10, CCL17, CCL18 and CCL22. They promote tissue repair, angiogenesis and tumor progression and 
additionally downregulate M1-mediated functions as well as adaptive immunity (Solinas et al. Journal of Leukocyte 
Biology 2009; 86: 1065-1073). 













TAMs originate from blood monocytes that are recruited to the tumor site by several factors 
including macrophage colony-stimulating factor (M-CSF), GM-CSF, IL-3 and chemokines like CCL2. 
Experimental and clinical studies in thyroid, lung and hepatocellular cancers demonstrated that 
high levels of tumor-infiltrating macrophages were often correlated with poor prognosis [31], 
[32]. One of the key players of macrophage regulation is M-CSF, which overexpression was also 
associated with poor prognosis in several cancer types [33], [34]. In the breast cancer model 
polyoma middle T (PyMT) genetic ablation of M-CSF reduced macrophage infiltration as well as 
tumor progression and metastasis [33]. Similar effect could be achieved with antibody treatment 
that inhibits M-CSF or its receptor [35].On the other hand, overexpression of M-CSF in wild-type 
tumors resulted in macrophage recruitment and increased tumor progression and metastasis.  
TAMs resemble a modified M2 phenotype and their functional polarization is a result of the 
absence of M1 signals in the tumor like IFN-γ or bacterial components. Furthermore, M2 
polarizing factors are highly presented and support their differentiation towards an IL-12low 
IL-10high phenotype. IL-10 secretion by TAMs promotes monocyte differentiation into 
macrophages and therefore avoids a differentiation to DCs [36]. An established gradient of IL-10 
also influence incoming monocytes by their localization within the tumor. In breast cancer TAMs 
were equally distributed throughout the tissue whereas DCs were only present in the periphery 
[37]. Sica et al. observed that murine TAMs displayed a defective NFκB activation in response to 
M1 signals confirming their low production of inflammatory cytokines (IL-12, IL-1β, TNF-α and  
IL-6) [38]. Moreover, TAMs were poor producers of NO due to their low expression iNOS and 
secrete only low levels of reactive oxygen species (ROS) [39]. Genetic profiling of TAMs revealed 
an upregulation of several M2-associated genes such as CD162, Fc fragment of IgG, C-type lectin 
domains and heat shock proteins, therefore supporting their role as M2 macrophages [40]. 
 
Figure 3.3: Macrophage subpo-
pulations during tumorigenesis 
Macrophages promote cancer 
progression. Shown are six 
macrophage functions that support 
tumor growth. Each function can be 
ascribed to a unique macrophage 
subpopulation  
(Qian et al Cell 2010; 141: 39-51). 
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3.4.1 Functions of TAMs 
 
According to the M2 phenotype, TAMs have several pro-tumoral functions contributing to tissue 
remodeling and repair, promotion of angiogenesis and skewing inflammatory responses and 
adaptive immunity (Figure 3.4). 
Angiogenesis. TAMs contribute to angiogenesis by producing multiple pro-angiogenic factors like 
TGF-β, VEGF, platelet derived growth factor (PDGF) and members of the fibroblast growth factor 
(FGF) family. In human cervical cancer, TAMs favor lymphoangiogenesis and formation of 
lymphatic metastasis through the release of VEGF [41]. In lung cancer, PDGF production by TAMs 
was proposed to support tumor progression [42]. Another feature of TAMs that promote 
angiogenesis is the production of various chemokines. Several studies indicated that secretion of 
CXCL12, CCL2, CXCL8, CXCL1, CXCL13 and CCL5 was involved in angiogenic processes including 
neo-vascularization [43], [44]. Production of these pro-angiogenic factors was further supported 
by the ability of TAMs to preferentially accumulate in hypoxic regions characterized by low oxygen 
levels. Hypoxia triggers a pro-angiogenic program which is mainly regulated by the transcription 
factors HIF-1 and HIF-2 (hypoxia-inducible factor-1/2). They induce expression of several pro-
angiogenic factors such as VEGF, FGF, CXCL8 and CXCL12, which in turn amplify angiogenic 
responses [45].  
Matrix remodeling and metastasis. TAMs support tumor invasion and metastasis by producing 
factors that can cleave the extracellular matrix and disrupt basal membrane. These factors include 
enzymes like MMP2 and MMP9. In several tumors MMP2 and MMP9 expression was highly 
increased, which was correlated with increased metastatic potential [46]. Moreover, chemokines 
like CCL5 or factors such as TNF-α, IL-1β and VEGF can further increase the expression of MMPs 
resulting in an enhanced invasiveness of malignant cells [47], [48]. 
Suppression of adaptive immunity. The third feature of TAMs is to suppress adaptive immune 
responses directly through the secretion of immunosuppressive cytokines and indirectly through 
the release of chemokines. Due to the high activity of IL-10 and defective NFκB pathway, low 
levels of immune stimulatory cytokines like TNF-α, IL-1 and IL-12 are produced resulting in 
decreased anti-tumor immune responses [38]. Mantovani and colleagues demonstrated that 
TAMs were poor antigen presenting cells but showed high potential to suppress T cell activation 
and proliferation via TGF-β and IL-10 [49], [23]. In addition, TAMs abrogate immune responses by 
their release of chemokines. In ovarian cancer it was shown that CCL18 attracted naïve T cells that 
became anergic in the tumor environment [50]. Moreover, by attracting Tregs to the tumor 
through the secretion of TAM-derived CCL17 and CCL22, anti-tumoral T cell responses were 
abolished [51].  







3.4.2 Therapeutic targeting of TAMs 
 
Since TAMs support tumor growth and represent up to 50% of the tumor mass, therapeutic 
targeting of these cells might be an attractive approach for immunotherapy. Up to date three 
different strategies exist: (a) inhibition of TAM recruitment to tumor site, (b) blocking their pro-
angiogenic functions and (c) reversal of their suppressive phenotype towards pro-inflammatory 
macrophages. 
Recruitment. Recently it has been reported that Trabectedin, a natural product derived from the 
marine organism Ecteinascidia turbinata, exhibited anti-tumor activity with cytotoxic effect on 
monocytes and macrophages, including TAMs. While sparing the lymphoid population, 
Trabectedin reduced the production of CCL2 and IL-6 both in TAMs and tumor cells [52]. In the 
murine breast cancer model 410.4, it was shown that tumor cells recruited macrophages via CCL5. 
Treatment with Met-CCL5, a receptor antagonist for CCR5, decreased the level of TAMs along 
with reduced tumor size [53].  
Angiogenesis and metastasis. VEGF plays an important role in monocyte recruitment to the 
tumor but also in neo-vascularization of tumors. Therefore, blocking of VEGF and its receptor 
Figure 3.4: Origin and function of tumor-associated macrophages 
Monocytes are recruited through the blood stream to the tumor site via CCL2, M-CSF and VEGF where they 
differentiate into TAMs. TAMs resemble M2 macrophages and support tumor growth and metastasis and 
downregulate adaptive immunity (Solinas et al. Journal of Leukocyte Biology 2009; 86: 1065-1073). 
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seemed to be a promising strategy. Anti-VEGF neutralizing antibody therapies could decrease 
metastasis whereas specific inhibition of VEGFR reduced macrophage infiltration into the tumor 
[54]. Another molecule, zoledronic acid, inhibits efficiently MMPs. Zoledronic acid treatment in 
murine cervical cancer suppressed MMP9 expression by infiltrating macrophages and blocked its 
activity, therefore reducing premalignant lesions and tumor growth [55].  
Suppression. Shifting the M1-M2 balance towards M1 phenotype is the third strategy to 
circumvent pro-tumoral features of TAMs. Multiple studies indicated that the activation of Toll-
like receptors like TLR9 stimulated M1 polarization of macrophages by inducing an inflammatory 
program [56]. Indeed, combination therapy of CpG, the ligand of TLR9, and anti-IL-10R antibody 
shifted infiltrating macrophages towards M1 phenotype and resulted in triggering innate immune 
responses [57].  
 
3.5 Myeloid-derived suppressor cells 
 
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells 
comprising macrophages, granulocytes, dendritic cells and other myeloid cells at different stages 
of differentiation. During tumor progression MDSCs accumulate in blood, lymph nodes, bone 
marrow and tumor site in cancer patients and tumor-bearing mice. These cells are potent 
suppressors of various T cell functions and their suppressive function is highly correlated with 
increased production of reactive oxygen and nitrogen species as well as elevated levels of 
arginase-1. 
 
3.5.1 Historical overview 
 
Studies in 1970s identified a formerly unknown cell population with suppressive features. These 
cells accumulated in bone marrow and spleen of tumor-bearing mice and were capable of 
suppressing T cell responses in vitro and in vivo [58], [59]. The term “natural suppressor cells” has 
been embossed and further characterization revealed their involvement in tolerance induction by 
inhibiting different effector functions of the immune system [60]. Subsequent studies described 
these cells as immature myeloid cells that were precursors of DCs, macrophages and 
granulocytes. Additional terms like “immature myeloid cells” (IMCs) or “myeloid suppressor cells” 
(MSCs) were used to specify their features. In 2007 the name “myeloid-derived suppressor cells” 
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3.5.2 Origin of MDSCs 
 
In the bone marrow of healthy individuals hematopoietic stem cells give rise to common myeloid 
precursor cells, which generate immature myeloid cells without suppressive function. Under 
normal conditions, these cells are released into the peripheral blood and migrate to peripheral 
lymphoid organs. In the periphery, they differentiate into mature macrophages, DCs or 
neutrophils. Several pathologic processes like infection, trauma, inflammation or cancer can block 
the differentiation of IMCs and thereby expanding this immature population and abrogating the 
development of functional effector cells. During tumor development or infection these cells can 
be activated in response to tumor- or pathogen-derived factors. As a result, IMCs differentiate 






3.5.3 Mouse MDSC subset definition 
 
MDSCs comprise a phenotypically heterogeneous population of myeloid cells, which are in mice 
characterized by the co-expression of the myeloid cell differentiation antigen Gr-1 and CD11b 
(αM-integrin) [62], [19]. In healthy mice, these cells display 20-30 % of bone marrow cells, 2-4 % 
of splenocytes and are absent from the lymph nodes. Recently, two morphological and functional 
distinct MDSC subpopulations were described based on their expression of Gr-1 (see 3.5.6). The 
Figure 3.5: The origin of MDSCs 
Myelopoiesis of immature myeloid cells (IMC) is controlled by soluble factors including GM-CSF, M-CSF, SCF, IL-3 and 
FLT3. Under healthy conditions, IMCs migrate to peripheral organs and differentiate into macrophages, DCs and 
granulocytes. Infection, trauma or tumor environment promote the accumulation of IMCs, prevent their 
differentiation and induce their activation to MDSC. (Gabrilovich et al. Nature Reviews Immunology 2009; 9: 162-174). 
Eva Schlecker  INTRODUCTION 
 
26 
Gr-1 antigen includes the macrophage and neutrophil markers Ly6C and Ly6G, which can be 
separately detected by antibodies specific for their distinct epitopes. The Ly6 family displays a 
group of low molecular weight molecules (12-20 kDa) that are phosphatidylinositol-anchored cell 
surface glycoproteins. Their triggering leads to a signal transduction resulting in T cell activation 
[63]. Using Ly6G and Ly6C markers, two MDSC subsets were identified: CD11b+Ly6G+Ly6Clow 
MDSCs morphologically resembling polymorphonuclear granulocytes (PMN-MDSCs) and 
CD11b+Ly6G-Ly6Chigh MDSCs with monocytic phenotype (MO-MDSCs) [64]. Analysis of different 
tumor models showed that during tumor growth both subpopulations expanded, but in most 
cases the accumulation of PMN-MDSC was more prominent [65].  
Novel studies defined an additional subset according to the Gr-1 staining intensities. CD11b+ 
splenocytes from different tumor models could be divided into Gr-1high, Gr-1int and Gr-1low cells. 
Gr-1high cells represented the PMN-MDSC subset, which exerted weak or no suppression on CD8+  
T cells. While Gr-1low cells resembled MO-MDSCs with strong suppressive potential, the Gr-1int 
subset displayed moderate suppression [66]. 
Further studies have identified additional phenotypic markers: including CD80 (B7.1) [67], CD115 
(M-CSF receptor) [68] and CD124 (IL-4 receptor α) [69]. However, the involvement of CD124 and 
CD115 in T cell suppression remains controversial. Bronte and colleagues proposed that the 
suppressive activity of MDSCs was exclusively restricted to CD124+ cells, whereas Youn et al. 
showed that MDSCs had the same ability to suppress T cell proliferation independent on CD115 
and CD124 [65], [69]. Overall, these studies suggested that MDSCs were not a defined subset of 
cells but rather a group of heterogeneous myeloid cells that share the common biological activity 
to suppress T cells.  
 
3.5.4 Human MDSCs 
 
The lack of a Gr-1 homologue in humans makes it difficult to identify human MDSCs. Since there 
are no specific markers known yet, human MDSCs are even less well defined than in mice. Several 
different combinations of surface molecules have been used to describe MDSCs in cancer patients 
based on their suppressive capacities. First reports characterized MDSCs as Lin-HLA-DR-CD33+ or 
CD14-CD11b+CD33+ cells [70], [71]. More recently, new markers have been associated with their 
function. In melanoma patients, the monocytic fraction expressing CD14+CD11b+HLA-DR-/low was 
identified to mediate immune suppression via TGF-β [72]. Similarly, monocytic CD14+ MDSCs with 
high arginase activity from hepatocellular carcinoma were observed to suppress autologous T cell 
proliferation and induced the expansion of IL-10 secreting regulatory T cells [73]. Similar to mice, 
several reports suggested CD124 as a MDSC marker in humans. Patients with non-small cell lung 
cancer showed an increased level of MDSCs expressing CD124, which were able to downregulate 
the expression of CD3ζ chain on CD8+ T cells [74]. Moreover, studies in melanoma patients 
revealed that the upregulation of CD124 correlated with an immunosuppressive phenotype of 
MO-MDSCs [75]. Rodriguez et al. proposed CD66b, a member of the carcinoembryonic antigen 
(CEA)-like glycoprotein family, as a marker for the granulocytic MDSC subpopulation in patients 
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with renal cell carcinoma [76]. Due to the heterogeneity of human MDSC populations the 
identification in cancer patient is challenging and further investigations are required to identify 
new and potentially unique markers.  
 
3.5.5 Expansion and activation of MDSCs 
 
Various findings indicated that tumor-derived factors (TDF) promoted not only MDSC expansion 
but also their activation toward an immunosuppressive phenotype. Table 3.1 summarizes factors, 
which influence MDSC expansion and their activation in mouse models and human cancers. 
FACTORS TUMOR MODEL (mouse) TYPE OF CANCER (human) 
 MDSC Expansion    
 Prostaglandins Mammary carcinoma, lung cancer, renal and 
colon cancer 
 ND 
 Stem cell factor (SCF) Colon carcinoma  ND 
 M-CSF Sarcoma and mammary carcinoma  Human renal carcinoma cell lines 
 IL-6 Mammary carcinoma  ND 
GM-CSF Lewis lung carcinoma, colon carcinoma, 
mammary adenocarcinoma 
 Melanoma 
 G-CSF Lewis lung carcinoma, methA sarcoma, 
melanoma 
 ND 
 VEGF Breast cancer, sarcoma, melanoma, 
lymphoma, lung carcinoma 
Breast cancer, renal cell cancer, 
pancreatic cancer 
 S100A8 and S100A9 Colon carcinoma, lymphoma, fibrosarcoma, 
mammary carcinoma 
 ND 
MDSC Activation   
 IFN-γ Mammary adenocarcinoma, fibrosarcoma, 
colon carcinoma, lymphoma 
 ND 
 IL-4/IL-13 Colon carcinoma, fibrosarcoma, mammary 
adenocarcinoma, lymphoma 
 ND 
 TGF-β Colon carcinoma, fibrosarcoma, mammary 
adenocarcinoma 
 Head and neck cancer 
 IL-1β Fibrosarcoma, mammary carcinoma  ND 
 CCL2 Lewis lung carcinoma, methA sarcoma, 
melanoma, lymphoma 
 ND 




Table 3.1: Factors involved in MDSC expansion and activation 
Table adapted from Gabrilovich et al. Nature Reviews Immunology 2009; 9: 162-174 
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Mechanisms of MDSC expansion. Prostaglandins, stem cell factor (SCF), M-CSF, IL-6, GM-CSF and 
VEGF belong to the well studied factors that can induce MDSC expansion. In myeloid cells many of 
them are involved in the triggering of Janus kinase (JAK) and signaling transducer and activator of 
transcription 3 (STAT3) signaling pathways, which results in the expression of B cell lymphoma XL 
(Bcl-XL), cyclin D1, MYC and survivin (Figure 3.6). Subsequently, survival and proliferation of 
myeloid progenitor cells are increased [77]. Nefedova et al. observed that MDSCs from tumor-
bearing mice had elevated levels of phosphorylated STAT3 compared to healthy mice. 
Constitutive STAT3 activity prevented maturation of DCs and thereby promoted expansion of 
MDSCs [78]. Ablation of STAT3 in conditional knock-out mice impaired MDSC expansion and 
abolished suppressive activity of MDSCs in tumor-bearing mice [79]. Downstream of STAT3 
signaling the expression of calcium-binding pro-inflammatory proteins S100A8 and S100A9 is 
induced, whose receptors are expressed on MDSCs [80]. In vitro studies revealed that STAT3-
dependent upregulation of S100A8/A9 in hematopoietic progenitor cells inhibited DC and 
macrophage differentiation and promoted MDSC accumulation. Tumor-bearing mice lacking 
S100A9 showed a reduced level of MDSCs accompanied by tumor regression [81]. Sinha et al. 
reported that S100A8/A9 contributed to the recruitment of MDSCs to tumor sites through NFκB-
dependent pathways [82]. Moreover, accumulation of MDSCs in spleen was abrogated in mice 
deficient of the transcription factor C/EBP-β, which was controlled by STAT3 [83].  
Mechanisms of MDSC activation. Gabrilovich and colleagues have proposed that factors 
responsible for MDSC expansion were not sufficient to generate MDSC activity [84]. MDSCs seem 
to require a second activating signal to upregulate suppressive factors including arginase, NO and 
immune suppressive cytokines. The second signal is provided by activated T cells, tumor stromal 
cells and infected cells, which secret IFN-γ, ligands for TLRs, IL-4, IL-13, and TGF-β resulting in 
STAT1 and STAT6 signaling (Figure 3.6). Similar to STAT3 in MDSC expansion, STAT1 and STAT6 
play a central role in MDSC activation. STAT1 is the main transcription factor activated by IFN-γ 
and IL-1ß. STAT1 deficient MDSCs failed to inhibit T cell proliferation due to the inability to 
upregulate arginase or iNOS [85]. Activation of STAT6 by CD124 signaling results in the expression 
of arginase-1 and TGF-β, which increases the suppressive activity of MDSCs [86], [87]. Studies in a 
polymicrobal sepsis model revealed MDSC accumulation in spleen, which was dependent on the 
TLR adaptor protein MyD88. However, experiments with TLR4 deficient mice with bacterially 
induced sepsis demonstrated that MDSCs could still accumulate indicating that they might be 
activated through other TLRs [88].  



















3.5.6 MDSC-mediated suppression 
 
MDSCs suppress immunity by interfering with both innate and adaptive immune responses. First 
studies in mice demonstrated that MDSCs inhibited T cell responses by blocking their activation 
(IFN-γ production) and proliferation [62]. Subsequent reports showed that MDSC activity required 
cell-cell contact and could be antigen-specific or non-specific, dependent on the MDSC 
subpopulation [65]. The role of MDSCs suppressing NK cells is controversial. Some studies 
observed that they abrogated NK cell cytotoxicity against tumor cells and inhibited IFN-γ 
production by NK cells [89], [90]. On the contrary, it has been reported that monocytic MDSC 
expressing Rae-1, the ligand for NKG2D, activated NK cells to produce IFN-γ [91]. Moreover, cross-
talks between MDSCs and macrophages have been reported. High production of IL-10 by MDSCs 
converted macrophages to M2 phenotype, which resulted in downregulation of the macrophage 
type I cytokine IL-12 [92]. The following paragraph summarizes mechanisms that have been 
implicated in MDSC-mediated suppression. 
 
Figure 3.6: Signaling pathways involved in MDSC expansion and activation 
MDSC expansion and activation is regulated by several factors secreted by tumor cells, tumor stromal 
cells, T cells, macrophages and pathogens. These factors trigger different pathways involving STAT3, 
STAT6, STAT1 and NFκB. Once activated these transcription factors induce the expression of survival and 
cell cycle genes like myc, bcl-xl and cyclin D1 or genes like TGF-β, arginase-1 and iNOS, which are involved 
in T cell suppression. In addition, STAT3 triggers an alternative pathway leading to the expression of the 
pro-inflammatory proteins S100A8 and S100A9 and upregulation of reactive oxygen species (Gabrilovich 
et al. Nature Reviews Immunology 2009; 9: 162-174) 
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L-arginine metabolism. Initial studies associated the suppressive activity of MDSCs with the  
L-arginine metabolism. L-arginine is used for biosynthesis of the proteins creatine and agmatine 
and is mainly metabolized by the enzymes arginase and NOS to produce urea and L-ornithine, and 






Two arginase isoforms (Arg-1 and Arg-2) have been identified in mammals, which share 58% 
sequence identity at the amino-acid level. The liver-type arginase, Arg-1, is located in the 
cytoplasm of hepatocytes and is an important component of the urea cycle. Exposure to IL-4,  
IL-13, IL-10 or TGF-β upregulates Arg-1 via the transcription factor STAT6. The kidney-type Arg-2 is 
located in the mitochondria of renal cells, neurons and macrophages and is involved in L-proline 
synthesis [94]. In addition, three distinct isoforms of NOS have been described so far: nNOS 
(NOS1, in neuronal tissue), iNOS (NOS2, inducible in various cells of the immune system) and 
eNOS (NOS3, in endothelial cells). iNOS expression has been reported in macrophages, 
granulocytes, DCs and NK cells and can be induced by IFN-γ, LPS, IL-1, TNF and type I IFNs. These 
cytokines activate the transcription factors NFκB, AP1 and STAT1 [95].  
It was shown that MDSCs express Arg-1 and iNOS, either separately or in combination to inhibit 
immune responses. Rodriguez et al. observed that MDSCs expressing Arg-1 can take up L-arginine 
from the extracellular environment, which inhibits the re-expression of the CD3ζ chain after 
internalization by antigen-stimulated T cells [96]. CD3ζ is the main signal-transduction component 
of the TCR and is required for correct assembly of the receptor complex. Depletion of L-arginine 
and high production of urea alter the translation of mRNA in T cells resulting in repression of CD3ζ 
(Figure 3.9a). NO produced by iNOS mediates T cell suppression via mechanisms associated with 
the IL-2 signaling cascade. Uptake of NO by T cells leads to nitrosylation of crucial cysteine 
residues or to the activation of cyclic-GMP-dependent kinase [97]. These changes interfere with 
the IL-2 receptor signaling pathway by blocking the phosphorylation of kinases or by altering the 
IL-2 mRNA stability (Figure 3.8b).  
Reactive oxygen and nitrogen species. When both enzymes Arg-1 and iNOS are activated, the 
production of reactive oxygen and nitrogen species is initiated (e.g. superoxide O2
-, peroxynitirites 
ONOO-, hydrogen peroxide H2O2). ONOO
- is a product of the chemical reaction between O2
- and 
NO and represents a highly reactive oxidizing agent. In the cytoplasm of T cells it can induce post-
translational protein modifications by nitrating tyrosine, cysteine, methionine and tryptophan 
residues of proteins and thereby influencing enzyme activity, cell proliferation and survival [98]. 
H2O2 is induced by the interaction of O2
- with hydrogen protons (H+) from H2O. It is stable, diffuses 
Figure 3.7: L-arginine metabolism 
L-arginine is metabolized by arginase into urea 
and ornithine, which is used as a substrate for 
polyamine and proline synthesis. In addition  
L-arginine is degraded by NOS into NO and 
citrulline to produce creatine. (Rodriguez et al. 
Immunological Reviews 2008; 222: 180-191) 
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across membranes and can interfere the expression of B cell lymphoma 2 (Bcl2), CD95 ligand 






Figure 3.8: Arg-1 and iNOS activity involved in MDSC suppression 
MDSC-induced immune subversion is associated with the activity of Arg-1 and iNOS. a) Arg-1 activity increases 
urea and decreases L-arginine concentration from the microenvironment, which causes translational blockade 
of CD3ζ via the kinases mammalian target of rapamycin (MTOR) and kinase general control non-depressible 2 
(GCN2). b) iNOS produces NO, which nitrosylates cysteine residues in proteins and activates cyclic GMP 
resulting in the blockade of IL-2 receptor signalling. c) Both enzymes together shift the NO production towards 
peroxynitrite (ONOO
-
) and hydrogen peroxide (H2O2), which leads to nitration of tyrosin residues and changes 
in Bcl-2 and CD95L activity resulting in T cell apoptosis (Bronte et al. Nature Reviews Immunology 2005; 5: 641-
654) 
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Figure 3.9: Three ways of cysteine production by 
immune cells 
Ostrand-Rosenberg Cancer Immunology Immunotherapy 
2010; 59(10): 1593-1600 
Cysteine. Cysteine is an essential amino acid for T cells to synthesize proteins. In general, cells 
either produce cysteine from their intracellular pool of methionine using the enzyme 
cystathionase or they import cystine, the oxidized form of cysteine, via xc-transporter to reduce it 
intracellularly to cysteine. Since T cells lack cystathionase and xc-transporter, they depend on 
APCs to provide cysteine during antigen 
processing and presentation. In addition, 
APCs secrete thioredoxin which reduces 
extracellular cystine to cysteine (Fig 3.9) 
[100]. Srivastava et al. observed that MDSCs 
interfered with T cell activation by inhibiting 
cysteine uptake. By increasing extracellular 
cysteine levels they demonstrated that 
MDSC-induced T cell suppression could be 
reverted. Furthermore, they showed that 
MDSCs consumed cysteine but did not 
return it to their microenvironment due to 
the lack of the ASC transporter, which 
exports cysteine. Therefore, MDSC block  
T cell response by depriving cysteine from 
the surroundings [101].  
L-selectin. Naïve T cells migrate through the blood stream to draining lymph nodes where they 
become activated by antigen presenting cells. High expression of L-selectin (CD62L) on the surface 
directs T cells to their destined locations. L-selectin mediates extravasation of leukocytes from 
blood to lymph nodes but also to the tumor tissue. Recent studies demonstrated that reduced 
expression of L-selectin on T cells inversely correlated with MDSC levels in both cancer patients 
and tumor-bearing mice. This downregulation was caused by proteolytic cleavage and shedding of 
the L-selectin ectodomain by ADAM17 (a disintegrin and metalloproteinase domain 17). MDSCs 
constitutively express ADAM17 and thereby prevent T cell homing to lymph nodes or tumor sites 
[102]. 
Induction of regulatory T cells. MDSCs also indirectly inhibit T cell responses by inducing Tregs, 
which in turn block T cell activation. In murine colon carcinoma, MDSCs promote the 
development of Tregs from adoptively transferred CD25-CD4+ T cells in the presence of IL-10 and 
IFN-γ [68]. In other reports, MDSCs act as APCs to present tumor specific antigens to Tregs that 
expanded in an Arg-1-dependent and TGF-β-independent manner [87]. Yang et al. further 
observed a CTLA4-dependent (cytotoxic lymphocyte antigen 4, CD152) activation of Tregs by 
MDSCs. MDSCs express CD80, the ligand for CTLA4, and after deletion or blockage of CD80 the 
suppressive function of Treg was significantly downregulated [67]. Moreover, it has been 
demonstrated that the expression of the immune stimulatory receptor CD40 on MDSCs was 
required to induce T cell tolerance and Treg accumulation [103]. 
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3.5.7 Therapeutic targeting of MDSCs 
 
Since MDSCs are one of the main suppressive factors in cancer, several pharmacological 
approaches are currently under investigation that involves either their elimination or modulation. 
Such MDSC inhibitors can be divided into 4 groups according to their ability to control: (a) MDSC 
maturation from precursors, (b) MDSC differentiation into mature cells, (c) MDSC accumulation 
and (d) MDSC function.  
MDSC maturation. To block MDSC maturation from hematopoietic precursors this group of 
inhibitors has been developed with the ability to neutralize factors involved in MDSC expansion. 
As summarized in table 3.1, these factors are comprised of: prostaglandins, SCF, M-SCF, IL-6, GM-
CSF, G-SCF and VEGF. Since most of these factors trigger signaling pathways that activate STAT3, 
this transcription factor seems to be a promising therapeutic target. Collaborations of the 
National Cancer Institute, Merck, Sigma Aldrich and Ryan databases identified via in silico 
screening of chemical libraries two small molecules, STA-21 and S31-201, which are able to inhibit 
STAT3 [104]. Another strategy to inhibit STAT3 is using the platinum complex, CPA-7, which 
possesses anti-tumoral activity due to DNA cross-linking. CPA-7 treatment leads to the reduction 
of phosphorylated STAT3 levels in tumor-infiltrating DCs in line with increased NK response 
against tumor [79]. Recently, it was reported that sunitinib, a tyrosine kinase inhibitor, might 
target STAT3 in MDSCs from renal cell carcinoma. Receptor tyrosine kinases are surface molecules 
that transduce extracellular signals to the cytoplasm to activate Ras/Raf, STAT3 and protein kinase 
C pathways. Sunitinib is a broad inhibitor blocking VEGF receptor (VEGFR), platelet derived growth 
factor receptor (PDGFR), stem cell factor receptor (c-kit), Flt3 and M-CSF receptor. Sunitinib 
therapy of metastatic renal cell carcinoma patients correlated with a reduction of MDSCs, 
increased DC expansion [105], increased Th1 and reduced Th2 response together with diminished 
Treg populations [106]. 
MDSC differentiation. Promising approaches to target MDSCs is promoting their differentiation 
into mature cells in order to circumvent their suppressive features. It is known that vitamin A 
induces the differentiation of myeloid progenitor cells into DCs and macrophages. Studies using 
all-trans retinoic acid (ATRA), a derivate of vitamin A, demonstrated that administration of ATRA 
favored the differentiation of MDSCs into mature cells [107]. The main mechanism of ATRA-
mediated differentiation includes the upregulation of glutathione synthesis (GSS) and the 
reduction of ROS levels in MDSCs. In addition, reduced levels of MDSCs due to ATRA enhanced  
T cell responses against tumors [108]. Further, patients with head and neck cancer squamous cell 
carcinoma (HNSCC) were orally treated with vitamin D, which decreased the numbers of CD34+ 
suppressor cells and increased IFN-γ levels [109].  
MDSC accumulation. Previous studies used an in vivo administration of the Gr-1 antibody to 
deplete Gr-1+ MDSCs, which reversed T cell tolerance and reduced tumor progression. 
Unfortunately, a rapid accumulation of MDSCs was observed when the antibody concentration 
was decreased or its application interrupted [110]. Therefore, administration of 
chemotherapeutic drugs, such as gemcitabine, has been preferred. Gemcitabine is a nucleoside 
analog of cytidine, which causes chain termination when incorporated into DNA during 
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replication. Tumor-bearing mice treated with gemcitabine showed reduced numbers of splenic 
MDSCs and an improvement of anti-tumor immune responses that was associated with 
accelerated apoptosis of MDSCs [111]. Another chemotherapeutic drug, 5-Flurouracil (5-FU), 
functions as a pyrimidine analog and induces cell cycle arrest and apoptosis after incorporation 
into DNA and RNA. Like gemcitabine, in vivo treatment with 5-FU decreased splenic and tumor-
infiltrating MDSCs but had no effect on tumor progression [112].  
MDSC function. Another approach to inhibit MDSCs is to interfere with signaling pathways, which 
regulate the function of suppressive factors. ROS inhibitors like nitroaspirin had been shown to 
decrease MDSC-mediated immune suppression by downregulation of Arg-1 and iNOS in splenic 
MDSCs and by suppression of cancer cell proliferation. However, after end of administration no 
statistical difference in survival rates was observed between treated and untreated groups [113]. 
Another approach to block MDSC function is targeting phosphodiesterase 5 (PDE5). PDE5 reduces 
cGMP, which results in stabilizing the mRNA of Arg-1 and iNOS. Blockade of PDE5 with the PDE5 
inhibitor sildenafil showed increased levels of cGMP in line with decreased expression of CD124 
and diminished activity of Arg-1 and iNOS. Furthermore, recovery of T cell proliferation and an 
enhanced tumor infiltration of CD8+ T cells were detected [114]. Table 3.2 summarizes 
therapeutic approaches to inactivate MDSCs. Pharmacological MDSC inhibition seems to be a 
promising strategy to overcome tumor-induced immune suppression but therapeutic effects 
might be more efficient when used in combination with immunotherapy and not administered 
alone.  
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Table 3.2: Therapeutic strategies to target MDSCs 
Inhibitors to target MDSCs can be divided into four groups according to their ability to control: (a) MDSC 
differentiation into mature cells (b) MDSC maturation from precursors (c) MDSC accumulation in peripheral 
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4 AIM OF THE STUDY 
 
Myeloid-derived suppressor cells (MDSCs) have been characterized in cancer patients and tumor 
bearing mice based on their ability to suppress T cell responses. During tumor progression MDSCs 
accumulate in bone marrow, blood, peripheral lymphoid organs and in the tumor tissue. They 
represent a heterogeneous population of myeloid cells at different stages of differentiation. In 
mice these cells are characterized by the co-expression of the surface markers Gr-1 and CD11b. 
Within this population, two distinct MDSC subpopulations with clear morphological differences 
have been identified, comprising mononuclear cells (MO-MDSCs), which express Ly6C and the 
macrophage marker F4/80, and polymorphonuclear cells (PMN-MDSCs), which express Ly6G and 
do not display F4/80 surface expression.  
Increasing numbers of experimental and clinical studies suggest that for effective anti-tumor 
responses, effector cells of both innate and adaptive immunity have to be efficiently activated at 
the tumor site. So far, most studies had been focused on the analysis of MDSCs that accumulate 
in blood and spleen. The aim of our study was the comprehensive analysis of tumor-infiltrating 
MDSCs in comparison to blood MDSCs including their subset distribution, phenotype and 
function. In order to identify molecules and pathways that might be involved in MDSC regulation, 
gene expression profiling of blood and tumor-infiltrating MDSC subpopulations was performed 
using whole genome microarrays. We demonstrate that tumor-infiltrating MO-MDSCs displayed 
increased expression of genes involved in suppression, inflammatory responses and chemotaxis 
compared to blood MDSCs. Furthermore, we showed that chemokines produced by MO-MDSCs 
within the tumor played an important role in tumor progression by attracting Tregs. Therefore, 
our study reveals a novel aspect of MDSC function by recruiting Treg that should be considered in 
current therapeutic protocols for cancer treatment. 
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5 MATERIALS AND METHODS 
5.1 Materials 
5.1.1 Mouse strains 
 
C57BL/6 (WT) mice were purchased from Charles River Laboratories (Sulzfeld, Germany and 
Erembodegem, Belgium). CCR5 -/- mice and congenic C57BL/6-Ly5.1+ mice were purchased from 
Jackson Laboratory (Bar Harbor, Maine USA) and were bred in our animal facility. Congenic  
OT-I/Thy1.1 mice were kindly provided by Prof. G. Hämmerling. Mice were housed under specific 
pathogen-free condition and used in experiments at 7-19 weeks of age. All experiments were 
performed according to local animal experimental ethics committee guidelines. 
5.1.2 Cell lines 
 
Name Cell type Medium 
B16 Mouse melanoma DMEM 
MCA205 Mouse fibrosarcoma DMEM 
RMA-S TAP2-deficient variant of mouse T cell lymphoma 
RMA 
RPMI 
2.4G2 Anti-CD16/CD32 hybridoma DMEM 
 
5.1.3 Cell culture products 
 
Product Company Catalog No. 
Standard tissue culture flasks/filter screw caps – 25 cm
2
 TPP 90026 
Standard tissue culture flasks/filter screw caps – 75 cm
2
 TPP 90076 
Standard tissue culture flasks/filter screw caps – 150 cm
2
 TPP 90151 
Tissue culture flasks/filter screw caps – 182 cm
2
 Greiner 660175 
96-well flat-bottom with lid – Standard TC BD 353972 
96-well U-bottom with lid – Standard TC BD 353077 
24-well flat-bottom with lid – Standard TC BD 353047 
50 ml conical tubes Falcon
TM
 BD 352070 
15 ml conical tubes Greiner 188271 
5 ml round-bottom polypropylene test tubes BD 352008 
5 ml round-bottom polystyrene test tubes w/ cell strainer BD 352235 
Serological pipettes: 5, 10, 25 and 50 ml, sterile Costar 4487-4490 
40 µM cell strainer Falcon
TM
 BD 352340 
70 µM cell strainer Falcon
TM
 BD 352350 
Cryovial, 2 ml sterile Roth E309.1 
NalgeneTM Freezing Container, “Mr. Frosty” Nunc 5100-0001 
Eva Schlecker  MATERIAL AND METHODS 
 
38 
Safe lock tubes: 0.5, 1.5 and 2 ml Eppendorf 13625, 12682, 12776 
Filter tips: 10, 20, 100, 200, 300 and 1000 µl Biozym 770010,-50,-280,-300,-400 
50 ml Reagent Reservoirs, sterile Corning 4870 
 
5.1.4 Cell culture media 
 
Product Company Catalog No. 
RPMI 1640 (1x) w/o L-Glutamine GIBCO-Invitrogen 31870 
DMEM (1x) (High Glucose) with L-Glutamine, 4500 mg/L 
D-Glucose, w/o Sodium Pyruvate 
GIBCO-Invitrogen 41965 
D-PBS (1x) w/o Ca, Mg, Sodium Bicarbonate GIBCO-Invitrogen 14190 
Fetal Bovine Serum, Origin: EU approved GIBCO-Invitrogen 10270 
Penicillin/Streptomycin-Solution: 10,000 U Penicillin, 
10,000 µg/ml Straptomycin 
GIBCO-Invitrogen 15140 
L-Glutamine 200 mM (100x), 29.2 mg/ml GIBCO-Invitrogen 25030 
Non-essential amino acids (100x) GIBCO-Invitrogen 11140035 
Sodium Pyruvate MEM 100mM GIBCO-Invitrogen 11360088 
β-Mercaptoethanol 50 mM GIBCO-Invitrogen 31350010 
Trypsin-EDTA (1x) HBSS w/o Ca, Mg with EDTA GIBCO-Invitrogen 25300 
Dimethylsulphoxide Hybri Max (DMSO) Sigma-Aldrich D2650 
 
 
5.1.5 Magnetic cell sorting (MACS) 
 
Product Company Catalog No. 
Anti-APC Miltenyi Biotec 130-090-855 
Anti-CD11b Miltenyi Biotec 130-049-601 
Anti-DX5 Miltenyi Biotech 130-052-501 
Anti-Ly6G Miltenyi Biotec 130-092-332 
LD Columns Miltenyi Biotec 130-042-901 
LS Columns Miltenyi Biotec 130-042-401 




Product Company Catalog No. 
BCA
TM
 Protein Assay Kit Pierce 23227 
Bioplex cytokine reagent kit Biorad 171-304000 
Bioplex cell lysis kit Biorad 171-304011 
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Bioplex mouse MIP-1alpha assay Biorad 171-G5020M 
Bioplex mouse MIP-1beta assay Biorad 171-G5021M 
Bioplex mouse RANTES assay Biorad 171-G5022M 
Bioplex mouse MIG assay Biorad 171-G6005M 
Bioplex mouse MIP-2 assay Biorad 171-G6006M 
Bioplex mouse IL-13 assay Biorad 171-G5012M 
DCFDA Invitrogen D399 
FITC BrdU Flow Kit BD 557891 
Foxp3 Staining Buffer Set eBioscience 00-5523 
Griess Reagent R1/R2 Biozol 780018/780020 
Mouse Ref-6 v2 Illumina BD-202-0202 
Mouse CCL3 DuoSet R&D DY450 
Mouse CCL4 DuoSet R&D DY451 
Mouse CCL5 DuoSet R&D DY478 
Mouse IFN-γ OptEIA
TM
 Set BD 555138 
OptEIA
TM
 Reagent Set B BD 550534 
QuantiChrom Arginase Assay Kit BioAssay Systems DARG-200 
RNeasy Mini Kit Qiagen 74124 
TURBO DNA-free
TM




Primary antibodies Clone Company Catalog No. 
BrdU FITC PRB-1 eBioscience 11607142 
CD115 PE AFS98 eBioscience 12-1152 
CD11b FITC M1/70 BD 557396 
CD11b PE M1/70 Biolegend 101208 
CD124 PE mIL4R-M1 BD 552509 
CD14 PE Sa14-2 Biolegend 123310 
CD3 APC 145-2C11 Biolegend 100312 
CD31 FITC MEC13.3 BD 553372 
CD4 PerCP-Cy5.5 RM4-5 Biolegend 100540 
CD40 PE 3/23 BD 553791 
CD43 FITC S7 BD 553270 
CD49b PE DX5 BD 553858 
CD54 Alexa647 YN1/1.7.4 Biolegend 116114 
CD62L PE MEL-14 Biolegend 104407 
CD68 Alexa647 FA-11 Biolegend 137004 
CD8 FITC 53-6.7 Biolegend 100706 
CD80 FITC 16-10A1 Biolegend 104706 
CD86 PE GL1 BD 553692 
Dectin-2 PE D2.11E4 AbD Serotec MCA2415PE 
F4/80 Alexa488 BM8 Caltag MF48020 
F4/80 APC BM8 Caltag MF48005 
Foxp3 PE FJK-16s eBioscience 125773 
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Gr-1 APC RB6-8C5 Biolegend 108412 
Gr-1 PerCP-Cy5.5 RB6-8C5 Biolegend 108428 
H-2D
b
 PE KH96 BD 553574 
H-2K
b
 PE AF6-88.5 BD 553570 
I-A/I-E PE M5/114.15.2 BD 557000 
Ly6C bio HK1.4 Biolegend 128004 
Ly6G FITC 1A8 BD 551460 
NK1.1 PE PK136 Biolegend 108708 
panRae-1 PE 186107 R&D systems FAB17582P 
PD-L1 PE 10F.9G2 Biolegend 124308 
PD-L2 PE TY25 BD 557796 
TLR-4 bio UT41 eBioscience 13-9041-80 
 
Isotype controls Clone Company Catalog No. 
armenian hamster FITC HTK888 Biolegend 400906 
mouse IgG2b PE 133303 R&D systems IC0041P 
ratIgG2a FITC RTK2758 Biolegend 400506 
ratIgG2a PE RTK2758 Biolegend 400508 
ratIgG2b Alexa647 RTK4530 Biolegend 400626 
ratIgG2b PE eB149/10H5 eBioscience 12403183 
 
Secondary antibodies Clone Company Catalog No. 
SAv PE Strepatvidin Biolegend 405204 
SAv PerCP-Cy5.5 Streptavidin Biolegend 405214 
 
5.1.8 Chemicals and biological reagents 
 
Product Company Catalog No. 
7-AAD BD 559925 
All-trans retinoic acid (ATRA), 5 mg pellets Innovative Research of America V-111 
CCL3, recombinant mouse Peprotech 250-09-100 
CCL4, recombinant mouse Peprotech 250-32-100 
CCL5, recombinant mouse Peprotech 250-07-100 
Carboxyfluorescein succinimidyl ester (CFSE) Sigma-Fluka 21888 
Concavalin A Sigma C5275 
DNase I Sigma-Aldrich DN25 
Eosin Y Roth 7089.2 
Hematoxylin Roth T865.3 
Heparin-Sodium, 25,000 Units Braun 1708.00.00 
Hyaluronidase type V Sigma-Aldrich H6-254 
Isofluran B Braun 6724123.00.00 
Linear polyacrylamide (LPA) Ambion AM9520 
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Lipopolysaccharide (LPS) Sigma-Fluka L4391 
Lympholite M Cedarline CL5035 
[methyl-
3
H] Thymidine Amersham TRK637-5MCI 
Propidium Iodide (PI) Biolegend 421301 
RNA storage solution Ambion AM70000 





ACK lysis buffer 
0.829 g NH4Cl 
0.1 g KHCO3 
0.38 mg EDTA 
100 ml ddH2O                                                                           pH 7.3 
FACS buffer 
1x PBS 
0.02 % (v/v) NaN3 in PBS 
1 % FCS 






1 % FCS 
0.5 mM EDTA 
Primary cell culture medium 
1x RPMI 
10 % FCS 
2 mM L-glutamine 
100 U/ml Penicillin, 100 µg/ml Streptamycin 
1 mM Sodium pyruvate 
1x Non-essential amino acids 
0.25 mM β-mercaptoethanol 
10 x PBS 
1.37 M NaCl 
27 mM KCl 
100 mM Na2HPO4 (anhydrous) 
20 mM KH2PO4 
 
5.1.10 Laboratory equipment 
 
Equipment Name Company 
Anesthesia machine  Vapor 19.1 Drägerwerk AG 
Analytical scales  AE163 Mettler Toledo 
Beta-counter MicroBeta TriLux 1450 LSC Perkin Elmer 
Bioplex array system Luminex 100 Biorad 
Cell culture incubator Heraeus BBD 6220 (CO2) Kendro 
Centrifuge 5415 R (table) Eppendorf 
5417 R (table) Eppendorf 
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Zytospin 2 Shandon 
Heraeus Biofuge Pico Kendro 
Heraeus Multifuge 4 K-R/3 S-R Kendro 








Flow hood Heraeus Hera Safe BBD 6220 Kendro 
LabGuard NU-437-600E IBS Integra 
Freezer -20°C Premium, Comfort, Profi line Liebherr 
Freezer -86°C VIP series Sanyo 
Fridge Premium, Profi line Liebherr 
Harvester 96-well automated, TOMTEC PerkinElmer 
Ice machine  Hoshizaki 
Magnetic stirrer MR3001 K Heidolph 
Microscope Wllovert Hund Wetzlar 
BX51 Olympus 
N2 tank Cryosystem 6000 MVE 
pH meter pH211 Hanna Instruments 
photometer NanoPhotometer Implen 
Pump Econo Pump Biorad 
Thermomixer  Compact, Comfort Eppendorf 
Vortexer VortexGenie 2 VWR/Scientific Industries 
Water bath Heraeus Julabo TW20 Kendro 
 
  





5.2.1 Cell culture methods 
 
Thawing cells 
Frozen cryovials were shortly submerged in a 37°C water bath until 90 % of the cell suspension 
was thawed. The suspension was immediately diluted into 10 ml of appropriate medium and 
centrifuged (1200 rpm, 10 min, RT). Cells were resuspended in medium and cultured at 37°C, 5 % 
CO2. 
Splitting of adherent cells 
Adherent cells were washed once in PBS and pre-warmed Trypsin-EDTA was added in sufficient 
amounts to cover the cell layer. Cells were incubated at 37°C until complete detachment from the 
flask was observed under the microscope. After resuspending in culture medium, cells were 
collected in Falcon tubes and centrifuged (1200 rpm, 10 min, RT). Cells were subsequently diluted 
at different ratios into new flasks or used in experiments.  
Splitting of suspension cells 
Cells in suspension reaching an optimal density were split in ratios ranging from 1:5 up to 1:20 by 
adding the appropriate volume of medium. 
Determination of cell numbers 
An aliquot of cell suspension was diluted 1:1 with trypan blue solution (0.05 % w/v) to distinguish 
dead from live cells. Cells were counted with a Neubauer counting chamber (0.1 mm depth). The 
number of live cells per ml cell suspension was calculated as the following: 
Average cell number/chamber square (0.1 mm3) x dilution factor x 104. 
Freezing of cells 
For cell freezing, cell suspensions were centrifuged (1200 rpm, 10 min, RT) and the pellet was 
resuspended in freezing medium at a concentration of 5 x 106 cells/ml. 1.8 ml of cell suspension 
was aliquoted in cryovials and placed in freezing containers. After 24 h at -80°C vials were 
transferred to liquid nitrogen for long term storage. 
 
5.2.2 Mouse tumor models 
 
Tumor cell lines were harvested in the exponential growth phase and washed three times with 
PBS (1200 rpm, 10 min, 4°C). For RMA-S and MCA205 the cell concentration was adjusted to  
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1 x 107 cell/ml or 5 x 106 cells/ml for B16, respectively. Mice were injected subcutaneously into 
the right flank with 100 µl of tumor cell suspension. Every second day tumor growth was assessed 
with a caliper measuring along the perpendicular axes of the tumor and expressed as the product 
of the two (surface) or three (volume) diameters. In survival studies mice were sacrificed when 
the tumor surface exceeded 4 cm2.  
 
5.2.3 In vivo treatment of mice 
 
In vivo BrdU staining of proliferating MDSC 
RMA-S tumor-bearing mice were injected with 2 mg BrdU i.p. on day 19 after tumor cell 
inoculation. After 16 h mice were sacrificed and bone marrow, blood, spleen and tumor 
suspensions were prepared. MDSC subpopulations were analyzed for BrdU incorporation using 
the BD FITC BrdU Flow Kit according to manufacturer’s instructions. 
In vivo application of chemokines 
For tumor infiltration experiments, 1 µg recombinant chemokine were co-injected with the tumor 
cells. Chemokines (1 µg in 100 µl PBS) were re-injected intratumorally every third day.  
ATRA pellet implantation 
ATRA pellets (21-day release, 5 mg) or placebo pellets were implanted s.c. in the neck of RMA-S 
tumor-bearing mice on day 7 after tumor cell inoculation. Mice were sacrificed two weeks later 
and tumor infiltrates were analyzed.  
 
5.2.4 Organ dissection and preparation of single cell suspensions 
 
Blood 
Mice were sacrificed by asphyxiation with CO2 and blood was obtained by heart puncture or by 
puncture of the orbital vein. Per mouse 0.7-1 ml blood was collected and subsequently mixed 
with 40 µl heparin. To obtain cell lysis, blood was treated with 30 ml of ACK buffer and further 
washed with PBS (1500 rpm, 10 min, 4°C). 
Spleen 
Animals were sacrificed by dislocation of the neck. The spleen was excised using sterile forceps 
and kept in ice-cold PBS. Single cell suspensions were obtained by mincing the spleen through a 
70 µm cell strainer followed by washing with PBS (1500 rpm, 10 min, 4°C). For the erythrocyte 
lysis, splenocytes were treated with 1.5 ml ACK buffer per spleen and washed with PBS. 




Tumor bearing mice were sacrificed by dislocation of the neck and tumor was excised using sterile 
forceps. Subsequently, tumors were cut into small pieces and digested in 10 ml digestion buffer 
(0.5 mg/ml hyaluronidase type V, 0.5 mg/ml DNase I) for 30 min at 37°C. Single cell suspension 
was obtained by mincing the digested tumor through a 70 µm-pore cell strainer. Cells were 
collected in a 50 ml Falcon tube and washed with PBS (1500 rpm, 10 min, 4°C). Pellet was 
resuspended in 8 ml of PBS and filtered through a 40 µm-pore strainer. Live cells were enriched by 
centrifugation (1500 g, 20 min, RT) of cell suspension loaded on 7 ml Lympholite M gradient and 
subsequent collection of the interphase. Cells were washed with PBS (1500 rpm, 10 min, 4°C). 
Bone marrow 
Animals were sacrificed by dislocation of the neck and the hind legs were dissected. Under sterile 
conditions bones were freed from all sinews and muscle tissue. Femur and tibiae were separated 
by breaking the knee and the heel, washed briefly in 80 % ethanol and placed in PBS. To rinse out 
the bone marrow cells, the ends of the bones were cut and rinsed out with 5-10 ml PBS using a 
27G needle. The isolated bone marrow was filtered through a 70 µm-pore cell strainer followed 
by washing with PBS (1500 rpm, 10 min, 4°C). To remove erythrocytes, cells were subsequently 
treated with ACK buffer und washed one more time.  
 
5.2.5 Cell staining 
 
Surface staining 
1 x 106 cells from culture or primary cells from organs were washed and resuspended in 100 µl 
FACS buffer. To block Fc receptors, 10 % 2.4G2 supernatant was used and incubated for 15 min at 
4°C. Appropriate antibodies were added and cells were further incubated for 30 min at 4°C in the 
dark. When biotinylated antibodies were used, cells were washed with FACS buffer and incubated 
with conjugated streptavidin for an additional 30 min at 4°C. After staining, all samples were 
washed in FACS buffer to remove unbound antibodies. Samples were acquired FACSCalibur® flow 
cytometer and data was analyzed using CellQuest software. 
Intracellular staining 
Like surface staining, cells were collected and stained for surface markers. At the end of the 
staining procedure, samples were washed with FACS buffer and fixed using 
Fixation/Permeabilization Buffer (eBioscience) according to manufacturer’s instruction. Cells were 
further permeabilized with Permeabilization buffer (eBioscience) and incubated with 20 % 2.4G2 
supernatant for 30 min at 4°C in 100 µl total volume of Permeabilization Buffer. Intracellular 
molecules were stained with the appropriate antibody for 45 min at 4°C. Samples were washed in 
Permeabilization Buffer to remove unbound antibodies and resuspended in FACS buffer for 
analysis.  
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Hematoxylin & Eosin staining (H&E) 
Sorted cells were washed once with PBS and resuspended at a final concentration of 1 x 106 
cells/ml. 100 µl cell suspension was brought onto poly-L-lysin-coated microscopic glass slides 
(Sigma-Aldrich) by centrifugation using a cytospin instrumentation (800 rpm, 5 min, RT). Cells on 
the slides were fixed in 4 % PFA in PBS for 10 min and washed in PBS. Nuclei were stained with 
Mayer’s Hematoxylin (Dako Cytomation) for 5 min at RT. Excess Hematoxylin was removed by 
washing extensively with running water for 10 min. Subsequently, cytosol was counter-stained 
with 10 % Eosin Y (Applichem) for 5 min. Excess Eosin was removed by washing with running 
water for 10 min. Cells were dehydrated with an ethanol range starting with 70 % ethanol for 3 
min, 96 % ethanol for 3 min and finally with 100 % ethanol for another 3 min. Cells were then 
washed twice with xylol for 3 min and cells were mounted with coverslips using Vitro-Clud.  
 
5.2.6 Cell separation 
5.2.6.1 Magnetic cell sorting (MACS) 
 
MDSC subpopulations 
Single cell suspensions prepared from blood were resuspended in PBS at a concentration of 
 5 x 108 cells/ml and treated with 10 % 2.G42 supernatant for 15 min at 4°C. PMN-MDSCs were 
positively selected using Ly6G magnetic beads (Miltenyi Biotech) according to the manufacturer’s 
instructions. To isolate MO-MDSCs, the negative fraction of the Ly6G MAC sort was further used 
and 1 x 108 cells/ml were stained with 5 µl anti-Gr-1-APC antibody per 107 cells for 15 min at 4°C. 
MO-MDSCs were then isolated via positive selection with anti-APC beads (Miltenyi Biotech) 
according to the manufacturer’s instructions. 
T cells 
Single cell suspensions prepared from naïve spleens were washed with MACS Buffer and 
resuspended at 1 x 108 cells/ml. Cells were treated with 10 % 2.4G2 supernatant for 15 min at 4°C. 
T cells were isolated via negative selection with pan T cell isolation kit (Miltenyi Biotech) according 
to the manufacturer’s instructions. 
NK cells 
Single cell suspensions prepared from naïve spleens were washed with MACS Buffer and 
resuspended at 1 x 108 cells/ml. To block Fc receptors, splenocytes were incubated in 10 % 2.4G2 
supernatant for 15 min at 4°C and positively selected for DX5+ cells using DX5 magnetic beads 
(Miltenyi Biotech). 
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5.2.6.2 Fluorescence activated cell sorting (FACS) 
 
Blood MDSCs 
Single cell suspensions prepared from blood were resuspended in PBS at a concentration of  
5 x 108 cells/ml and treated with 10 % 2.G42 supernatant for 15 min at 4°C. MDSC subpopulations 
were pre-separated using Ly6G magnetic beads (Miltenyi Biotech) according to the 
manufacturer’s instructions. Ly6G+ fraction containing PMN-MDSCs and the negative fraction 
containing MO-MDSCs were subsequently stained with fluorochrome labeled anti-Gr-1 and anti-
F4/80 antibody for 30 min at 4°. After washing (1500 rpm, 10 min, 4°C) cells were resuspended in 
PBS at a concentration of 5 x 107 cells/ml and filtered through a 30 µm cell mesh. Propidium 
iodide (PI) was added to the cell suspension 10 min prior sort to label dead cells. PI-Gr-1+F4/80- 
PMN-MDSCs and PI-Gr-1+F4/80+ MO-MDSCs were sorted using FACSDiva® or FACSInflux® cell 
sorter instruments. 
Tumor-infiltrating MDSCs 
Single cell suspensions prepared from tumors were enriched via anti-Gr-1-APC and anti-APC beads 
according to the manufacturer’s instructions. The positive fraction was washed with PBS and 
resuspended at 5 x 107 cells/ml. MDSCs were subsequently stained with a fluorochrome labeled 
anti-F4/80 antibody for 30 min at 4°C. After washing cells were filtered through a 30 µm cell mesh 
and PI was added to the cell suspension 10 min prior sort to label dead cells. PI-Gr-1+F4/80- PMN-
MDSCs and PI-Gr-1+F4/80+ MO-MDSCs were sorted using FACSDiva® or FACSInflux® cell sorter 
instruments. 
Tumor-associated macrophages 
Single cell suspensions prepared from tumors were enriched via CD11b beads (Miltenyi Biotech) 
according to the manufacturer’s instructions. The positive fraction was washed with PBS and 
resuspended at 5 x 107 cells/ml. TAMs were subsequently stained with fluorochrome labeled anti-
F4/80, anti-CD11b and anti-Gr-1 antibodies for 30 min at 4°C. After washing cells were filtered 
through a 30 µm cell mesh and PI was added to the cell suspension 10 min prior sort to label dead 
cells. PI-CD11b+F4/80+Gr-1- TAMs were sorted using FACSDiva® or FACSInflux® cell sorter 
instruments. 
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5.2.7 Functional assays 
 
5.2.7.1 Proliferation assays 
 
3H-Thymidine incorporation 
PMN- or MO-MDSCs were sorted by flow cytometry and co-cultured with 1 x 105 splenocytes from 
naïve mice at different effector/target ratios. To stimulate T cell proliferation either 2 µg/ml ConA 
(Sigma) was added or pre-coated plates with 1 µg/ml anti-CD3/CD28 antibodies were used. Cells 
were cultured for 72 h and 1 µCi of 3H-Thymidine was added for the final 18 h of culture. After 
incubation cells were harvested and 3H-Thymdine incorporation was measured using MicroBeta 
TriLux Counter (Perkin Elmer). 
CFSE dilution 
Naïve T cells from C57BL/6-Ly5.1 mice were enriched via pan T cell isolation kit (Miltenyi) and  
1 x 107 cells/ml were labeled with 1 µM CFSE. Cells were cultured for 10 min at 37°C and washed 
twice with primary cell culture medium. 1 x 105 T cells were co-cultured with FACS sorted MDSC 
subsets at different effector/target ratios. T cell proliferation was induced using either 2 µg/ml 
ConA (Sigma) or pre-coated plates with 1 µg/ml anti-CD3/CD28 antibodies. After 3-4 days cells 
were harvested and T cells were stained with fluorochrome labeled anti-CD45.1, anti-CD4 and 
anti-CD8 antibodies. T cell proliferation (CFSE dilution) was analyzed by flow cytometry. 
 
5.2.7.2 Suppressive activity of MDSC subsets 
 
Arginase activity 
MDSC subpopulations were FACS sorted and 6 x 105 cells were washed in PBS. Pellets were 
resuspended in 100 µl lysis buffer (0.4 % TritonX-100 with 10mM Tris-HCl and protease inhibitors) 
for 30 min at 4°C. Samples were centrifugated (20000g, 10 min, 4°C) and supernatants were used 
for arginase assay. Arginase activity was measured using the QuantiChrom arginase assay kit 
(BioAssay Systems). 
Nitrite/NO production 
MDSC subpopulations were FACS sorted and 5 x 105 cells were cultured in 200 µl primary cell 
medium with and without 1 µg/ml LPS. Supernatants were collected after 24h and 100 µl were 
mixed with 0.5 volume Griess Reagent R1 and 0.5 volume Griess Reagent R2. After 10 min of 
incubation the absorbance at 540 nm was measured. Nitrite concentrations were determined by 
comparing the absorbance values for the test samples to a standard curve generated by serial 
dilution of 0.25mM sodium nitrite. 




Oxidative sensitive dye DCFDA (Invitrogen) was used to measure ROS production by MDSC 
subsets. Single cell suspensions from blood and tumors were incubated at 37°C in PBS containing 
2.5 µM DCFDA for 30 min. For induced activation, cells were simultaneously cultured with  
30 ng/ml PMA. After incubation cells were labeled with anti-Gr-1 and anti-F4/80 antibodies and PI 
was added to exclude dead cells. Analysis was conducted by flow cytometry (FACSCalibur®).  
 
5.2.8 Quantification of chemokines and cytokines 
 
Enzyme-linked immunosorbent assay (ELISA) 
To quantify IFN-γ production by T cells or NK cells, 105 cells were cultured alone or co-cultured 
with sorted MDSCs at different effector/target ratios in primary cell culture medium 
supplemented with the appropriate stimuli for 12-96 h. Protein levels were measured by IFN-γ 
ELISA (BD) according to the manufacturer’s instructions. 
To determine chemokine levels, FACS sorted MDSC subpopulations were cultured in primary cell 
culture medium for 24 h. Supernatants were analyzed using the murine CCL3, CCL4 and CCL5 
ELISA (R&D) according to the manufacturer’s instructions. 
Bioplex protein array  
For the determination of cytokine and chemokine production by MDSCs, subpopulations of naïve 
and blood and tumor from tumor-bearing mice were FACS sorted. 5 x 104 cells were cultured in 
100 µl primary cell culture medium for 24h. Supernatants were collected and further diluted 1:1 
with Bioplex Sample Diluent (Biorad). Cytokine and chemokine release was determined with the 
Bioplex Protein Array according to the manufacturer’s instructions. 
 
5.2.9 Gene expression profile analysis 
 
Experimental setup 
Groups of 30 mice were injected subcutaneously with PBS (naïve controls) or groups of 25 mice 
were subcutaneously injected with 106 RMA-S cells resuspended in 100 µl PBS. Mice were 
sacrificed on day 20 post-injection. Single cell suspensions were prepared from blood and tumor. 
PMN- and MO-MDSCs were isolated from the pooled blood and tumor samples as described in 
5.2.6.2. Sorted cells showed a purity of ≥98 %. Biological triplicates were collected for each group 
(naïve, tumor-bearing), each organ (blood, tumor) and each subpopulation (PMN-, MO-MDSC). 
 




RNA was isolated from MDSC subpopulations using RNeasy Mini Kit (Qiagen). Cells were lysed in 
RLT buffer according to manufacturer’s instructions and lysates were stored at -80°C until 
continuing isolation. Obtained RNA was treated with DNase using TURBO DNA-free kit (Ambion) 
in order to remove any possible genomic DNA contamination. 
RNA precipitation 
20 µg/ml linear polyacrylamide (LPA), 0.1 volume 3 M NaAc pH 5.2 and 4 volumes 100 % ethanol 
was added to 50 µl RNA solution and incubated for 30 min at -80°C. RNA was pelleted (16000g, 30 
min, 4°C) and washed twice with ice-cold 75 % ethanol. Pellets were dried to remove any 
remaining ethanol for max. 2 min and resuspended in RNA Storage Solution (Ambion). Quantity 
and quality of obtained RNA was analyzed using RNA Pico Assay performed on the Bioanalyzer 
2100 Lab-on-a-Chip system. High quality RNA samples were chosen for microarray experiment. 
Microarray experiment 
Gene expression was detected using Mouse Ref-8 v2 array from Illumina. Six experimental groups 
were examined, with triplicates for each group. cDNA and cRNA synthesis, and hybridization to 
arrays were performed according to the manufacturer’s instructions.  
Microarray data analysis 
Raw microarray data were processed using BeadStudio v9. Briefly, raw values were quantile 
normalized, background substracted and log2-transformed. Statistical and cluster analysis was 
performed using software package MeV v4.6 (MultiExperiment Viewer) from TM4 Microarray 
Software Suite. Statistical Analysis of Microarrays (SAM) was used to identify significantly 
regulated genes among groups under study. Unless otherwise stated a false discovery rate (FDR) 
of 5 % was utilized as a cutoff for determination of significance. Only genes, which showed a fold 
change ≥ 1.5.were analyzed,  
Microarray pathway analysis 
To identify pathways that are likely to be affected by differential expression, an ORA approach 
using Fisher's exact test was performed. Analyzed pathways were collected from the KEGG 
database (Kyoto Encyclopedia of Genes and Genomes). 
 
5.2.10 Statistical analysis 
 
Differences between groups were calculated using unpaired Student’s t-test. Differences in 
survival between groups of mice were calculated using log-rank test. Values of P < 0.05 were 
considered to be statistically significant. 
 





6.1 Characterization of tumor-infiltrating MDSC subpopulations 
 
6.1.1 Tumor-infiltrating MDSCs consist of a mononuclear and polymorphonuclear 
fraction 
 
So far, most studies had been focused on MDSCs that accumulate in spleens of different tumor 
models [115], [64], [65]. Movahedi et al. demonstrated that splenic Gr-1+CD11b+MDSCs consisted 
of a Ly6G+SSChigh polymorphonuclear (PMN) and a Ly6G-SSClow mononuclear (MO) fraction.  
MO-MDSCs express the macrophage marker F4/80 whereas it is absent on the PMN-MDSC subset 
[64]. The goal of our study was to characterize MDSC subsets, which infiltrated the tumor with 
regards to their phenotype and function. In our experiments, we used the TAP2-deficient mouse 
lymphoma model RMA-S derived from C57BL/6. Subcutaneous injection of the RMA-S cell line 
resulted in continuous tumor growth and expansion of Gr-1+CD11b+ MDSCs in blood, spleen and 
tumor after three weeks of tumor progression (Figure 6.1A). Blood from naïve mice contained 
10.7 %, whereas the naïve spleen showed up to 4.8 % of Gr-1+CD11b+ cells. A significant increase 
in the proportion of MDSCs (blood 20.8 %; spleen 8.2 %) as well as 1.2 % of tumor-infiltrating  
Gr-1+CD11b+ cells were observed in mice bearing RMA-S tumors after 19 days of tumor cell 
inoculation. 
In concordance to previous reports, Gr-1+CD11b+ cells in tumor-bearing mice consisted of two 
major subfractions based on differential expression of F4/80 (Figure 6.1B left panel). To further 
investigate the characteristics of these MDSC subpopulations, surface stainings for the Ly6G and 
Ly6C epitopes were performed. Gr-1+CD11b+F4/80- MDSCs from blood and tumor expressed both 
Ly6G and Ly6C (Figure 1B middle panel). While Gr-1+CD11b+F4/80+ MDSCs lacked the Ly6G 
epitope, they expressed Ly6C at high levels (Figure 1B right panel). Blood and tumor-infiltrating 
MDSCs did not differ in their expression of Ly6G and Ly6C. 
To address the question whether the two subpopulations display different morphologies, the 
nuclei of FACS sorted MDSC subsets from blood and tumor were analyzed (Figure 6.1C). Both  
Gr-1+CD11b+F4/80- MDSCs from blood and tumor showed a polymorphonuclear morphology 
(these cells will be termed PMN-MDSCs), whereas Gr-1+CD11b+F4/80+ MDSCs were mononuclear 

































Figure 6.1: MDSCs in tumor-bearing mice consist of a polymorphonuclear and mononuclear subpopulation 
Mice were subcutaneously injected with 10
6
 RMA-S cells. MDSCs were analyzed on day 19 after tumor cell 
inoculation. A) Left Tumor growth was measured in regular time intervals. Right Blood, spleens and tumors were 
collected from RMA-S tumor-bearing mice or untreated naïve mice. Cell suspensions were stained for Gr-1 and 








 were stained for their 
F4/80 expression (left panel). Both subpopulations were further analyzed for Ly6G and Ly6C expression (middle and 












 MDSC subsets were purified as described in “Methods” 
and subjected to hematoxylin and eosin staining. Magnification 200 x. Data are representative of three (A,B) and two 
experiments (C).  
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6.1.2 Phenotypic analysis of tumor-infiltrating MDSC subsets 
 
To gain further insight in the lineage commitment and potential function of MDSC subpopulations 
in blood and tumor, the expression of different surface markers, as described earlier [64], was 
analyzed (Figure 2). The IL-4 receptor α (CD124) was expressed on both subsets from blood and 
on MO-MDSCs from the tumor. However, tumor-infiltrating PMN-MDSCs displayed only low 
surface expression of CD124. The macrophage marker CD115 (M-CSF receptor) was absent on 
blood PMN-MDSCs, slightly expressed on MO-MDSCs and highly expressed on tumor-infiltrating 
MDSCs. CD68 (macrosialin), which is associated with a monocytic/macrophage phenotype, was 
predominantly expressed by the MO-MDSC subpopulation. The adhesion molecules CD54, CD43, 
CD31, CD49b and CD62L showed differential expression patterns. Whereas CD54 was absent on 
PMN-MDSCs from blood and hardly detectable on PMN-MDSCs from the tumor, it was highly 
expressed on the monocytic counterpart. PMN-MDSCs from blood exhibited high levels of CD43 
expression compared to the other subsets. CD49b was detected only on MDSCs from blood, 
whereas CD62L and CD31 were expressed on all subsets in all organs. In addition, we screened for 
surface markers, which are involved in antigen presentation. Although MHC class I molecules and 
CD86 were highly expressed on all MDSC subsets, only tumor-infiltrating MDSCs showed high 
expression of MHC class II and CD40 suggesting a higher potential for antigen presentation to 
CD4+ T cells. Also molecules involved in interaction with T cell were detected. CD80 was slightly 
expressed on all subsets, whereas PD-L1 expression was detected on an elevated surface level. 
Furthermore, the NKG2D ligand Rae-1, reported earlier as an additional marker for the monocytic 
subset [91], was highly expressed on tumor-infiltrating MO-MDSCs.  







6.1.3 Accumulation of MDSC subsets in the RMA-S tumor model 
 
To determine the kinetics of PMN- and MO-MDSC accumulation, the total cell number of the two 
subsets in blood and tumor was measured at various time points after tumor cell inoculation 
(Figure 6.3A). In blood, both subpopulations were induced during tumor progression. However, 
PMN-MDSCs were the more prominent subpopulation. Tumor-infiltrating subsets accumulated 


















Figure 6.3: Kinetics of tumor-induced MDSC subset accumulation 
The accumulation of PMN- and MO-MDSCs was analyzed during tumor progression. A) 10
6
 RMA-S cells were 
injected subcutaneously into 20 C57BL/6 mice and accumulation of MDSC subsets was analyzed in regular time 













) was determined by flow cytometry 
analysis. Values represent the mean ± SD (n=3-4). 
Figure 6.2: Phenotype of MDSC subsets 
Mice were subcutaneously injected with 10
6
 RMA-S cells. MDSCs were analyzed on day 19 after tumor cell 
inoculation. Subsets from blood and tumor were characterized for the expression of various surface markers 












). Stainings are 
representative of a pool of 2-3 mice.  
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6.1.4 MO-MDSCs show a high proliferation rate  
 
Several studies observed that tumor progression stimulated hematopoiesis in spleen [116], [117]. 
To address the origin and dynamics of tumor-infiltrating MDSCs, we analyzed the turnover of 
PMN- and MO-MDSCs by BrdU incorporation. After 16 hours of in vivo labeling, 1 % of PMN-
MDSCs and 13 % of MO-MDSCs in the bone marrow were BrdU positive. Less than 1 % PMN-
MDSCs in blood, spleen and tumor showed BrdU incorporation, suggesting that precursors of 
PMN-MDSCs in the peripheral tissue extravasated at these sites after expansion and mobilization 
from the bone marrow. Moreover, up to 8 % of MO-MDSCs in spleen and tumor exhibited BrdU 










6.2 Gene expression profile of tumor-infiltrating MDSC subsets 
 
So far, most studies had been focused on the analysis of MDSCs that accumulated in blood and 
spleen. Therefore, the aim of our study was the comprehensive analysis of tumor-infiltrating 
MDSCs including their subset distribution, phenotype and function. We performed a global gene 
expression profiling of tumor-infiltrating MDSC subpopulations from RMA-S tumor-bearing mice. 
In order to identify molecules and pathways that might be involved in functional regulation of 
MDSCs, additional blood MDSC subsets from naïve and tumor-bearing mice were included in our 
experimental setup (Figure 6.5A). PMN- and MO-MDSCs were isolated from blood of naïve mice 
and from blood and tumor of tumor-bearing mice on day 19 after tumor cell inoculation. To 
obtain highly purified MDSC subsets (≥ 96 %), cells were sorted by flow cytometry. Subsequently, 
total RNA was isolated from sorted cells and tested for its quantity and quality (Figure 6.5B). High 
quality RNA was labeled and hybridized with mouse whole genome microarrays. Each 
experimental group comprised biological triplicates.  
Figure 6.4: Turnover of MDSC subpopulations 
RMA-S tumor-bearing mice were systemically 
injected with BrdU on day 19 after tumor cell 
inoculation. After 16 h BrdU uptake by PMN- and 
MO-MDSCs from bone marrow, blood, spleen and 
tumor was analyzed by flow cytometry. Data are 
representative of two experiments. All values 
represent the mean ± SD (n=2). 











The dataset of the mouseWG-6 v2.0 expression bead chip contained expression levels for 45.200 
transcripts. Based on the Complete Linkage method and the Pearson’s correlation coefficient as a 
measure of similarity in the Chipster software, hierarchical cluster analysis was performed to 
group the samples according to the degree of similarity present in the gene expression data. In 
the resulting dendrogram five distinct clusters were detected (Figure 6.6). Due to the high 
similarity of PMN-MDSCs from naïve and tumor-bearing blood, these groups formed one cluster 
(red). One replicate of the MO-MDSC group (purple) from tumor-bearing mice had to be 
excluded, since this sample did not cluster with its dedicated group. In the dendrogram shown 
below, MO-MDSCs from naïve (blue) and tumor-bearing blood (purple) were the most similar and 
formed the first node, followed by tumor-infiltrating MO-MDSCs (green). The last two clusters 
(PMN-MDSCs from tumor = yellow; PMN-MDSCs from blood = red) joined latest, showing the 
largest difference to the MO-MDSC clusters.  
Figure 6.5: Experimental setup of the gene expression analysis 
A) 30 mice per group were subcutaneously injected with 10
6
 RMA-S cells or with PBS (naïve controls). On day 19 
after tumor cell inoculation PMN-MDSCs and MO-MDSCs were isolated from blood and tumor tissue. Each group 
was represented by biological triplicates. B) Highly purified MDSC subsets were obtained by flow cytometry 
sorting (left). Samples with purity ≥ 96 % were selected for RNA isolation. Total RNA was analyzed for quantity 
and quality using RNA 6000 Pico Assay performed on the Bioanalyzer 2100 Lab-on-a-Chip system (right). RNA of 
similar high quality was labelled and hybridized with Mouse Ref-6 v2 Illumina microarray chips. C) Comparisons of 
differently regulated genes were performed on tumor-infiltrating MDSC subsets (PMN-MDSC vs MO-MDSC) or on 
MO-MDSC from different organs (blood vs tumor). 




















Functional classification of differently expressed genes between blood and tumor-infiltrating 
MDSCs revealed their involvement in the control of immune responses (Table 6.1). Most 
significantly affected pathways in tumor-infiltrating MDSCs included the MAPK signaling pathway 
(MO-MDSC) and unexpectedly, the T cell receptor signaling pathway (PMN-MDSC). The MAPK 
signaling pathway comprised upregulated genes like CD14, Jun, Hras1, Raf1, Akt2 and IL-1β, which 
are involved in the regulation of cell proliferation, differentiation and inflammation. The T cell 
receptor signaling exhibited genes like CD3ε, ZAP70, Itk, NFAT as well as CD28, PI3K, Akt and 
Gsk3b, suggesting effector functions typically triggered upon CD3ε and CD28 engagement. Of 
note, CD3ε protein expression on MDSCs was detected by flow cytometry (data not shown). 
  
Figure 6.6: Hierarchical cluster analysis of MDSC subsets 
The schematized dendrogram reflects the process of clustering microarray samples according to the similarity 
in their gene expression profiles as measured by the Pearson correlation coefficient. Distances between the 
array sample clusters are approximated by the vertical axis. Along the x axis of the dendrogram the 
microarray replicates are listed  




Pathway Affected subset  Hits Percentage Significance 
MAPK signaling  MO-MDSC 20 4.1 0.0044 
Toll-like receptor signaling MO-MDSC 9 1.8 0.11 
Renal cell carcinoma MO-MDSC 10 2.0 0.0025 
T cell receptor PMN-MDSC 11 2.4 0.0044 
Apoptosis PMN-MDSC 9 2.0 0.0098 
DNA replication PMN-MDSC 6 1.3 0.013 
VEGF signaling PMN-MDSC 8 1.8 0.02 





In the second analysis, comparisons between tumor-infiltrating PMN-MDSCs and MO-MDSCs 
were made. MO-MDSCs within the tumor significantly upregulated genes of the lysosome 
pathway, including lysosmal acid hydrolases (cathepsins A/B/C/H/Z; Lamp1; neuraminidase-1) and 
CD68, suggesting a high activity in phagocytosis. In addition, several genes involved in antigen 
processing and presentation were detected, such as MHC class I, MHC class II and CD74. This 
finding indicates that tumor-infiltrating MO-MDSCs might play an important role in cross-talks 
with T cells and NK cells.  
 
Pathway (MO-MDSCs) Hits Percentage Significance 
Lysosome 24 4 0.0000 
Systemic lupus erythematosus 12 2.0 0.017 
Antigen processing and presentation 11 1.8 0.022 
Sphingolipid metabolism 7 1.2 0.047 
Cell adhesion molecules 14 2.3 0.055 
 
 
Table 6.1: Signaling pathways affected by differential gene expression in tumor-infiltrating MDSCs 
To identify pathways that are likely affected in tumor-infiltrating MDSCs from RMA-S injected mice, an ORA 
(overrepresentation analysis) approach using Fisher’s exact test was performed. Pathways were analyzed using the 
DAVID software according to the KEGG (Kyoto Encyclopedia of Genes and Genomes) database.  
Table 6.2: Signaling pathways affected by differential gene expression subsets of tumor-infiltrating MDSCs 
To identify pathways that are likely affected between tumor-infiltrating PMN-MDSCs and MO-MDSCs, an ORA 
approach using Fisher’s exact test was performed. Pathways were analyzed using the DAVID software according to 
the KEGG database.  




Moreover, when we focused on the tumor-infiltrating MO-MDSC 
subpopulation, the pan-genomic analysis revealed a cluster of 
more than 400 genes, which were explicitly upregulated in MO-
MDSCs from the tumor tissue compared to all other samples 
(Figure 6.7). Within this cluster, we found genes that have been 
associated with suppression (e.g. arginase-1), inflammation (e.g. 
CD14, Dectin-2) and chemotaxis (e.g. CCL3/4/7/24). The following 











6.2.1 Tumor-infiltrating MO-MDSCs upregulate expression of genes involved in 
suppression 
 
MDSCs are potent suppressors of various T cell functions. Their suppressive activity is highly 
correlated with increased production of reactive oxygen and nitrogen species as well as elevated 
levels of arginase-1 [118]. Several studies have suggested that the mononuclear subset rather 
than the polymorphonuclear fraction is responsible for T cells suppression through iNOS and 
arginase-1 [119] [118]. Consistent with previous findings showing that arginase-1 was mainly 
expressed in MO-MDSCs, its transcript was highly increased in the tumor-infiltrating MO-MDSCs 
compared to all other subsets from all organs in our experiment (Figure 6.8A). Next, we analyzed 
the arginase-1 activity to validate significant changes on protein levels. MDSC subpopulations 
from blood and tumor of RMA-S injected mice were FACS sorted and their arginase-1 activity 
measured. In addition to the transcriptional level, the arginase-1 activity of tumor-infiltrating MO-
MDSCs was highly increased, whereas comparably low levels were measured in the PMN-MDSC 
subsets. 
Figure 6.7: Genes upregulated in tumor-infiltrating MO-MDSCs 
Differently expressed genes were identified and clustered according to their 
upregulation in tumor-infiltrating MO-MDSC subset using the MeV 
(MultiExperimentViewer) analysis software. Genes were sorted corresponding 
to their log2 value of 5.9 to 14.0. NB = naïve blood; TB = blood from tumor-
bearing mice; T = tumor; MO = MO-MDSC; PMN = PMN-MDSC 








In addition to arginase-1, also other factors are involved in T cell suppression. We asked, whether 
tumor-infiltrating MDSC subsets might display higher levels of iNOS or ROS. Although neither the 
iNOS gene nor genes involved in ROS production were upregulated on transcriptional levels (data 
not shown), iNOS activity via NO secretion and the production of ROS were evaluated. In response 
to stimulation with LPS, monocytic MDSCs produce significantly higher levels of NO than their 
granulocytic counterpart (Figure 6.9A). In contrast, PMN-MDSCs from blood of tumor-bearing 
mice displayed significantly higher levels of ROS production than PMN-MDSCs from the tumor 




Figure 6.8: Tumor-infiltrating MO-MDSC upregulated arginase-1 
The arginase-1 expression profile of MDSC subpopulations from naïve blood, RMA-S blood and from RMA-S tumors 
was analyzed. A) Relative expression levels of the arginase-1 gene in different MDSC subsets are expressed as the Log2 
intensity value. Values represent the mean ± SD (n=3). B+C) MDSC subpopulations from blood and tumor of RMA-S 
injected mice were sorted and their arginase-1 activity was measured as described in “Methods”. B) Total levels of 
arginase-1 activity. C) Fold increase of arginase-1 activity in tumor-bearing MDSC subsets compared to blood MDSCs. 
Arginase-1 activity of blood MDSCs was set at 1. 
Figure 6.9: Suppressive activity by MDSC subpopulations 
A) Sorted population of MDSCs were stimulated with 1 µg/ml LPS for 24 h, supernatants were collected and the 
nitrite/NO concentration was measured as described in “Methods”. ND, not detected B) MDSCs from blood and tumor 












 (MO) and their ROS production 
was determined via mean fluorescence intensity of DCFDA before and after 30 min of PMA stimulation. Data are 
representative of two experiments. All values represent the mean ± SD. 
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Together, these experiments showed that MO-MDSCs from tumor tissue exhibited high  
arginase-1 and iNOS activity compared to their blood counterpart. These findings suggested a 
potential role of tumor-infiltrating MO-MDSCs in T cell suppression. In contrast to MO-MDSCs, 
PMN-MDSCs displayed high ROS levels in blood, whereas in the tumor, a reduction in ROS was 
detected.  
 
6.2.2 Tumor-infiltrating MDSCs upregulate the expression of pro-inflammatory genes 
 
It has been shown that MDSCs accumulate in response to pro-inflammatory mediators that 
induce a variety of suppressive mechanisms to block both innate and adaptive anti-tumor 
immunity [120-121]. In addition to responding to pro-inflammatory signals, MDSCs also 
contribute to the inflammatory tumor microenvironment by secreting factors like IL-6 or 
S100A8/A9 [82]. We asked whether the tumor-infiltrating MO-MDSC subset display an 
inflammatory phenotype and thereby, might contribute to tumor progression.  
We found that the CD14 gene expression was significantly upregulated in tumor-infiltrating MO-
MDSCs, whereas it was downregulated in the polymorphonuclear subset compared to blood 
(Figure 6.10A). At protein level we confirmed increased expression of CD14 on tumor-infiltrating 
MO-MDSCs. Interestingly, although transcript levels of CD14 was decreased in tumor-infiltrating 
PMN-MDSCs, CD14 expression at protein level was increased compared to blood PMN-MDSCs 






Figure 6.10: Upregulation of CD14 on tumor-infiltrating MO-MDSCs 
The CD14 expression profile of MDSC subpopulations from naïve blood, RMA-S blood and from RMA-S tumors was 
analyzed A) Relative expression levels of the CD14 gene in different MDSC subsets are expressed as the Log2 
intensity value. B) Different MDSC subpopulations from blood and tumor of RMA-S injected mice as well as from 
naïve blood were stained for CD14 surface expression. Graph indicates the mean fluorescence intensity (MFI) of the 
different experimental groups containing a pool of three animals. Data are representative of one (A) and two (B) 
experiments. 
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The CD14 molecule acts as a co-receptor, and together with TLR-4, binds bacterial compounds like 
LPS [122] or pro-inflammatory molecules such as S100A8/A9 [123]. Triggering of the CD14/TLR-4 
complex leads to the activation of two distinct signaling pathways. One pathway is activated by 
the adaptor protein MyD88 (myeloid differentiation primary response gene 88), which results in 
induction of the pro-inflammatory cytokines TNF-α and IL-1, IL-6 and IL-10. The second pathway 
functions via the adaptor TRIF (TIR-domain-containing adapter-inducing interferon-β) leading to 
the induction of type I interferons IFN-α and IFN-β [124].  
 
To evaluate the protein level of the co-
receptor TLR-4, MDSC subpopulations from 
blood and tumors were stained for TLR-4 
surface expression. Like CD14, tumor-
infiltrating MO-MDSCs exhibited an increased 
expression of TLR-4, whereas no changes 
were detected on the PMN-MDSC subset 
(Figure 6.11). These data indicate that 
elevated levels of the CD14/TLR-4 complex 
might result in an increased activation of the 
TLR-4 signaling cascade. Therefore, we 
focused on target genes which were 
upregulated in tumor-infiltrating MO-MDSCs. 
Using the DAVID software according to the 
KEGG database we found several potential 
target genes of TLR-4 induced transcription 
factors, which were significantly upregulated 
in our microarray analysis (Table 6.3).  
 
Gene name Gene symbol Fold change 
Inflammatory 
cytokines 
Tumor necrosis factor tnf 3.06 
Chemokine (C-C motif) ligand 3 ccl3 10.12 
Chemokine (C-C motif) ligand 4 ccl4 9.58 
Chemokine (C-X-C motif) ligand 10 cxcl10 1.26 
Chemokine (C-X-C motif) ligand 9 cxcl9 3.22 
Co-stimulatory 
molecules 
CD 40 antigen cd40 2.25 




Figure 6.11: Expression of TLR-4 on different MDSC 
subpopulations 
Different MDSC subsets from blood and tumor of 
RMA-S injected mice as well as from naïve blood 
were stained for TLR-4 surface expression. Graph 
indicates the mean fluorescence intensity (MFI) of 
the different experimental groups containing a pool 
of three animals. Data are representative of two 
experiments. 
Table 6.3: Target genes of TLR-4 induced transcription factors  
To identify potential target genes that might be upregulated in the tumor-infiltrating MO-MDSC subset, KEGG 
pathway analysis for TLR-4 signaling was performed. The fold change of differently expressed target genes compared 
to all other subsets is shown. 
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In addition to CD14 and TLR-4, Dectin-2 (dendritic cell-associated C-type lectin-2) was significantly 
upregulated in the tumor-infiltrating MO-MDSC subpopulation. Dectin-2 belongs to the C-type 
lectin family, a protein group which was originally defined by their ability to recognize 
carbohydrate structures [125]. The receptor is mainly expressed on tissue macrophages, DCs and 
peripheral blood monocytes, where expression levels are transiently increased upon induction of 
inflammation [126]. Via its CRD domain (carbohydrate recognition domain), Dectin-2 recognizes 
zymosan, numerous pathogens and mannose [127], [128]. So far, the only endogenous ligand was 
detected on Tregs upon UV irradiation [129]. Dectin-2 has a short cytoplasmic domain which lacks 
signaling motifs and thereby, associates with FcRγ to transduce signals. Triggering of the receptor 
leads to the activation of the transcription factor NFκB and production of TNF-α and IL-1 receptor 
antagonists [128]. So far, the role of Dectin-2 in the tumor microenvironment is unclear.  
We found that the Dectin-2 gene clec4n was significantly upregulated in tumor-infiltrating  
MO-MDSCs, whereas it was downregulated in the polymorphonuclear subset compared to blood 
(Figure 6.12A). In addition, we confirmed that Dectin-2 is highly expressed on the cell surface of 
tumor-infiltrating MO-MDSCs. Despite the reduction of mRNA levels discovered by the microarray 
analysis, slightly increased surface levels of Dectin-2 on tumor-infiltrating PMN-MDSCs were 






So far, we showed that the inflammatory molecules CD14, TLR-4 and Dectin-2 were highly 
upregulated on both RNA and protein levels in tumor-infiltrating MO-MDSCs from RMA-S tumors. 
To confirm that this expression profile is not restricted to lymphoma tumors, we analyzed MDSC 
subpopulations from tumors of different origin. Like in lymphoma, in B16 melanoma and MCA205 
Figure 6.12: Upregulation of Dectin-2 on tumor-infiltrating MO-MDSCs 
The Dectin-2 expression profile of MDSC subpopulations from naïve blood, RMA-S blood and from RMA-S tumors 
was analyzed A) Relative expression levels of the Dectin-2 gene in different MDSC subsets are expressed as the Log2 
intensity value. B) Different MDSC subpopulations from blood and tumor of RMA-S injected mice as well as from 
naïve blood were stained for Dectin-2 surface expression. Graph indicates the mean fluorescence intensity (MFI) of 
the different experimental groups containing a pool of three animals. Data are representative of one (A) and two (B) 
experiments. 
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fibrosarcoma MO-MDSCs exhibited the same pattern of CD14 and Dectin-2 expression (Figure 
6.13). Compared to RMA-S and MCA205 tumors, tumor-infiltrating PMN-MDSCs from B16 






In summary, our data demonstrated that tumor-infiltrating MO-MDSCs exhibited an inflammatory 
phenotype by expressing high levels of CD14, TLR-4 and Dectin-2. Triggering of these receptors 
might result in the production of pro-inflammatory cytokines TNF-α, IL-1, IL-6 or IL-10 and thereby 
further contribute to a pro-inflammatory tumor microenvironment.  
 
 
Figure 6.13: Expression of inflammatory molecules on MDSC subsets from tumors of different origin 
Mice were subcutaneously injected with 5x10
5
 B16 melanoma and 10
6
 MCA205 fibrosarcoma cells. MDSCs were 
analyzed on day 15 (B16) and on day 25 (MCA205) after tumor cell inoculation and subsets from blood and 
tumor were characterized for the expression of the inflammatory surface markers CD14, TLR-4 and Dectin-2 by 
flow cytometry. A) Histograms indicate the expression levels of the different experimental groups containing a 
pool of three animals. B) Values show fold increase of expressed proteins from (A) in tumor-infiltrating MDSCs 
compared to blood. Data are representative of two experiments. 
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6.2.3 Tumor-infiltrating MO-MDSCs upregulate the expression of chemokines 
 
Chemokines play an important role in tumor growth and dissemination. They are not only key 
mediators in homing of cancer cells to metastatic sites but also in the recruitment of different cell 
types to the tumor microenvironment. Chemokines are classified based on the presence of 
conserved cysteine motifs in the protein sequence. The first group, CC subfamily (juxtaposition of 
the first two cysteines), comprises 28 members, whereas the CXC group (single variable amino 
acid between the first two cysteines) is composed of 17 members. In addition two smaller 
subgroups, CX3C and XC, are defined [130].  
 
It has been shown that the migration of MDSCs to the tumor is mediated by CCL2. MDSCs 
ubiquitously express the CCL2 receptor CCR2 and blockade of this interaction resulted in reduced 
recruitment and decreased tumor growth [131], [132]. However, chemokine secretion by MDSCs 
and their influence on cell recruitment and tumor growth has not been described so far. Our data 
demonstrated that several chemokine genes were significantly upregulated in tumor-infiltrating 
MO-MDSCs compared to other subsets (Figure 6.14). CCL3, CCL4, CXCL2, CXCL9, CCL7 and CCL24 






Figure 6.15 summaries all chemokines, which were upregulated in tumor-infiltrating MO-MDSCs. 
Shown are their dedicated receptors and the expression pattern of the chemokine receptors.  
 
 
Figure 6.14: Upregulation of chemokines in tumor-infiltrating MO-MDSCs 
The chemokine expression profile of MDSC subpopulations from naïve blood, RMA-S blood and from RMA-S tumors 
was analyzed. Shown are the Log2 intensity values of chemokine gene expression for Ccl3, Ccl4, Cxcl2, Cxcl9, Ccl7 
and Ccl24 in different MDSC subsets. 










In order to validate the chemokine profile, MDSC subpopulations were freshly isolated from blood 
and tumor of RMA-S tumor-bearing mice as well as from naïve blood. In addition, sorted TAMs 
and the tumor cell line RMA-S were included in our study. The production of CCL3, CCL4, CXCL2 
and CXCL9 was assessed after 24 h of culture in medium. CCL7 and CCL24 were excluded, since 
reagents for CCL7 and CCL24 could not be provided by the manufacturer, whereas the chemokine 
CCL5 was further included. The results demonstrated consistently higher chemokine levels 
produced by tumor-infiltrating MO-MDSC compared to other subsets. Moreover, lower levels of 
all five chemokines were observed in cultures of TAMs, suggesting that these cells might also 




Figure 6.16: Increased chemokine production by tumor-infiltrating MO-MDSCs 
C57BL/6 mice were subcutaneously injected with 10
6
 RMA-S cells. 19 days after tumor cell inoculation MDSC 






) were purified and cultured in vitro with medium for 24 h. The RMA-S cell 
line was cultured as a control. Supernatants were analyzed for chemokine production by Bioplex as described in 
“Methods”. Data are representative of two experiments. 
Figure 6.15: The chemokine 
system involved in tumor-
infiltrating MO-MDSCs 
Chemokines, their receptors and 
expression patterns are shown. 
Th1, T helper 1 cell; NK, NK cell; 
Mo, monocyte; Mφ, macro-
phage; Tact, activated T cell; Ba, 
basophil; iDC, immature DC; B,  
B cell; Eo, eosinophil; Th2,  
T helper 2 cell. 
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To confirm that this expression profile was not restricted to lymphoma tumors, the same 
approach was performed using the melanoma tumor B16. Like in lymphoma, MDSCs in B16 
melanoma displayed similar chemokine productions (Figure 6.17). The tumor-infiltrating  
MO-MDSC subset was the most potent producer of CCL4, CXCL2 and CXCL9, while CCL3 and CCL5 




6.3 Interaction of tumor-infiltrating MDSC subpopulations with immune 
cells 
 
MDSCs suppress immunity by inhibiting both innate and adaptive immune responses. Previous 
studies demonstrated that MDSCs could block the activation and proliferation of CD8+ and CD4+  
T cells. The suppressive activity requires cell-cell contact and is either antigen-specific or non-
specific [133]. Tumor immunity is also impacted by the interaction of MDSCs and NK cells. 
Dependent on the tumor model MDSCs inhibit NK cell cytotoxicity against tumor cells and block 
IFN-γ production or activate NK cells due to Rae-1, that interacted with NKG2D on NK cells [90], 
[91]. Here we analyzed the interaction of tumor-infiltrating MDSC subpopulations with T cells and 
NK cells. 
 
Figure 6.17: Increased chemokine production by tumor-infiltrating MO-MDSCs from B16 tumor model 
C57BL/6 mice were subcutaneously injected with 5x10
5
 B16 cells. 15 days after tumor cell inoculation MDSC subsets 
were purified and cultured in vitro with medium for 24 h. The B16 cell line was cultured as a control. Supernatants 
were analyzed for chemokine production by Bioplex as described in “Methods”.  
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6.3.1 Functional properties of tumor-infiltrating MDSCs cultured with T cells 
 
Since high levels of arginase-1 and iNOS activity was detected in MO-MDSCs from the tumor, we 
examined whether tumor-infiltrating MDSC subsets from RMA-S tumor-bearing mice suppress the 
proliferation of T cells. MDSC subpopulations from the tumor were isolated and sorted by flow 
cytometry. Highly purified subsets were cultured in the absence or presence of CFSE-labeled pan 
T cells from naïve C57BL/6-Ly5.1 congenic mice at indicated ratio together with ConA. After four 
days, T cell proliferation via CFSE dilution was determined. Unexpectedly, we detected an 
increased T cell proliferation when co-cultured with MO-MDSCs or PMN-MDSCs compared to  
T cells alone (Figure 6.18A). A dose-dependent effect of MDSCs on T cell proliferation was 
detected, when T cells were cultured with different MDSC ratios (6.18B). In summary, despite the 
fact that tumor-infiltrating MO-MDSCs showed increased levels of arginase-1 and iNOS activity (as 













6.3.2 Effect of tumor-infiltrating MDSCs on NK cell function 
 
In our previous study we showed that MO-MDSCs from blood and spleen of RMA-S tumor-bearing 
mice did not suppress NK cell proliferation but rather activated them to produce high levels of 
IFN-γ. This induction was partially mediated via the interaction with NKG2D on NK cells [91]. We 
asked whether the tumor-infiltrating MO-MDSC subset exhibits similar functional properties. As 
shown in Figure 6.2, tumor-infiltrating MO-MDSCs display elevated levels of Rae-1 compared to 
PMN-MDSCs. To determine the effect of MO-MDSCs on IFN-γ production, NK cells from naïve 
mice were cultured with IL-12 in the presence or absence of tumor-infiltrating MO-MDSCs. In  
Figure 6.18: Tumor-infiltrating MDSCs induce 
T cell proliferation 
C57BL/6 mice were subcutaneously injected 
with 10
6
 RMA-S cells. On day 19 after tumor 
cell inoculation tumor-infiltrating MDSC 
subsets were purified and co-cultured with 
CFSE-labeled pan T cells from naïve C57BL/6-
Ly5.1 congenic mice at different ratios in the 
presence of ConA. A) Proliferation was 
assessed by CFSE dilution on day 4. Shown are 
histograms with T cells alone (no MDSC) and 





 T cells. B) Graph 
indicates the percentage of proliferating  
T cells within different ratios of the co-
cultures. Data show the mean of triplicate 
cultures ± SD and are representative of three 
experiments. 
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co-cultures with MO-MDSCs, IFN-γ production was highly increased compared to NK cells cultured 
alone (Figure 6.19). MO-MDSCs alone did not produce significant levels of IFN-γ. In summary our 









6.4 TLR-4 signaling in tumor-infiltrating MDSC subsets 
 
As shown in Figure 6.10, gene expression profiling and flow cytometric analysis of blood and 
tumor-infiltrating MDSC subpopulations revealed profound changes of CD14 on the 
transcriptional as well as protein level. In addition, upregulation of TLR-4 was detected (Figure 
6.11). Up to date, there are various ligands known to activate TLR-4 signaling, e.g. LPS [134], 
S100A8/A9 [135], and SAA3 [136]. To investigate the role of TLR-4 signaling in tumor-infiltrating 
MDSCs, we analyzed the effect of LPS stimulation in vitro.  
Recently, Hamerman et al. demonstrated that murine peritoneal macrophages stimulated with 
LPS upregulated NKG2D ligands. We examined whether LPS stimulation of different MDSC subsets 
induced the expression of Rae-1. Blood and tumor MDSC subsets from RMA-S tumor-bearing mice 
were activated in vitro with LPS and after 24 h the cells were stained for Rae-1 surface expression. 
While low levels of Rae-1 were seen on unstimulated MO-MDSCs, an increase in staining was 
detected on LPS-activated MO-MDSCs from the tumor (Figure 6.20A). Rae-1 levels on MO-MDSCs 
from blood remained unchanged, whereas no effect was observed on PMN-MDSC subsets (data 
not shown). To test whether the induction of Rae-1 is associated with increased production of 
pro-inflammatory cytokines, supernatants of cultured tumor-infiltrating MDSCs were analyzed the 
presence of the pro-inflammatory cytokines/chemokines TNF-α, CXCL2 and IL-10. As shown in 
Figure 6.20B, LPS stimulation of tumor-infiltrating MDSCs resulted in increased production of  
TNF-α and CXCL2 and slight induction of IL-10. In summary, triggering of TLR-4 signaling in tumor-
infiltrating MO-MDSCs led to the upregulation of Rae-1 expression and increased production of 
pro-inflammatory factors that might contribute to the modulation of innate immune responses, 
including NK cells. 
Figure 6.19: Tumor-infiltrating MO-MDSCs 
induce IFN-γ production by NK cells 
C57BL/6 mice were subcutaneously injected 
with 10
6
 RMA-S cells. On day 19 after tumor 
cell inoculation tumor-infiltrating MO-MDSC 
were purified and co-cultured with naïve NK 
cells in the presence of IL-12. Supernatants 
were harvested after 24 h and IFN-γ amounts 
were determined by ELISA. Data show mean of 
triplicate cultures ± SD. 








To test whether ligands other than LPS trigger TLR-4 signaling to upregulate Rae-1 expression, 
tumor-infiltrating MO-MDSCs were stimulated with S100A8, S100A9 and S100A8/A9 proteins. As 








6.5 Tumor-infiltrating MO-MDSCs and their chemokine network 
 
Chemokines levels determine chemoattraction of macrophages, neutrophils, and lymphocytes 
into tumor tissue. We demonstrated that the tumor-infiltrating MO-MDSC subset was a potent 
producer of certain chemokines. Among these, CCL3, CCL4 and CCL5 were the most abundant 
chemokines and they all share CCR5 as a common receptor. The role of CCR5 in cancer remains 
controversial. While CCR5 expression on tumor epithelia has been connected to tumorigenesis 
[137], some tumor therapies required a functional CCR5 signaling pathway [138]. Therefore, we 
investigated the impact of CCR5 and its ligands CCL3, CCL4 and CCL5 on RMA-S tumor progression 
using recombinant chemokines in vivo and CCR5 deficient mice. 
Figure 6.20: Tumor-infiltrating MO-MDSCs upregulate Rae-1 expression and production of pro-inflammatory 
molecules upon LPS stimulation 
C57BL/6 mice were subcutaneously injected with 10
6
 RMA-S cells. On day 19 after tumor cell inoculation Gr-1 
enriched MDSCs from the tumor were stimulated for 24h with 200 µg/ml LPS. A) Rae-1 surface expression on PMN-
MDSC and MO-MDSC was determined by flow cytometry. B) Supernatants of tumor-infiltrating MDSCs were 
harvested and cytokine/chemokine amounts were measured by ELISA. Data are representative of three experiments. 
Values represent the mean ± SD. 
Figure 6.21: Tumor-infiltrating MO-MDSCs upregulate 
Rae-1 expression upon stimulation with S100 proteins 
C57BL/6 mice were subcutaneously injected with 10
6
 
RMA-S cells. On day 19 after tumor cell inoculation Gr-1 
enriched MDSCs from the tumor were stimulated for 24h 
with 200ng/ml LPS, 5µg/ml S100A8, S100A9 or the 
heterodimer S100A8/A9. Rae-1 surface expression on 
tumor-infiltrating MO-MDSC was determined by flow 
cytometry. Bars indicate the expression levels of the 
different groups containing a pool of three animals. 
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6.5.1 Expression of the CCR5 receptor on immune cells 
 
To evaluate the role of CCL3, CCL4 and CCL5 in chemotaxis, we studied the expression profile of 
their receptor CCR5 in tumor-bearing mice. Different immune cells from blood, spleen and tumor 
were stained for CCR5 surface expression to analyze, which cell populations might be recruited to 
the tumor site via CCR5. MDSCs and TAMs (defined as CD11b+F4/80+Gr-1-) expressed no CCR5 in 
blood and spleen. However, when these cells infiltrated tumor tissue, CCR5 surface expression 
was detected (Figure 6.22). In addition, a subpopulation of Tregs in spleen expressed CCR5, whose 
expression was further increased in tumor-infiltrating Tregs. Splenic CD8+ and CD4+ effector T cells 
lacked CCR5 expression (data not shown). This finding suggested that Tregs might be 










6.5.2 Influence of exogenous CCR5 ligands on tumor progression  
 
We investigated whether CCL3, CCL4 or CCL5 were able to chemoattract certain immune cells in 
vivo and thus potentially mediate increased infiltration of CCR5 expressing cells into the tumor. It 
was shown that these chemokines can recruit myeloid cells and Treg [139], [140]. Therefore, we 
injected recombinant CCL3, CCL4 or CCL5 together with RMA-S cells. Intra-tumoral chemokine 
injections were continued every third day and tumor growth and survival was assessed. We 
observed accelerated tumor growth (Figure 6.23A) and impaired survival (Figure 6.23B) of mice 
injected with CCL3, CCL4 or CCL5.  
Figure 6.22: CCR5 expression by different 
immune cells. 
C57BL/6 mice were subcutaneously 
injected with 10
6
 RMA-S cells. On day 19 
after tumor cell inoculation, MDSC subsets, 
TAMs and Tregs from blood, spleen and 
tumor were analyzed for CCR5 surface 
expression via flow cytometry. Histograms 
indicate the expression levels of the 
different experimental groups containing a 
pool of three animals. Data are 
representative of three experiments. 


































Next, we analyzed whether diverged levels of tumor infiltrates might cause these changes in 
tumor progression. C57BL/6 mice were injected with RMA-S cells and chemokines and the 
amount of tumor-infiltrating myeloid cells and T cells was determined. The distribution of PMN-
MDSCs and TAMs among total tumor-infiltrating CD11b+ cells was not affected by chemokine 
injection. However, slight reduction of MO-MDSCs upon CCL3 and CCL4 injection was observed 
(Figure 6.24A). Moreover, CCL4 and CCL5 positively affected Treg accumulation resulting in 
decreased CD4/Treg and CD8/Treg ratios (Figure 6.24B). In summary, we concluded that intra-
tumoral injection of CCL4 and CCL5 might accelerate tumor growth that correlated with increased 






Figure 6.23: Acceleration of tumor growth and shortened survival mediated by recombinant CCR5 ligands 
C57BL/6 mice (n=5) were subcutaneously injected with 10
6
 RMA-S cells and intra-tumorally with 1 µg recombinant 
CCL3, CCL4, CCL5 or PBS every third day. A) Tumor growth was monitored for 17 days. B) Survival was assessed for 31 
days. Values represent the mean ± SD of each group. 








6.5.3 Influence of the CCR5 receptor on tumor progression 
 
In the second approach, we sought to disrupt the CCR5-mediated chemotaxis by using CCR5 
deficient mice. To investigate its impact on tumor progression, CCR5 knockout and wild type mice 
were injected with RMA-S cells and tumor growth and survival was monitored. We observed 
significant delay of tumor growth and prolonged survival in CCR5 deficient mice (Figure 6.25A). 
Analysis of tumor infiltrates on day 11 revealed increased levels of CD8+ and CD4+ T cells in CCR5 
deficient mice, which was correlated with higher ratios of CD4/Treg and CD8/Treg (Figure 6.25B). 
Moreover, accumulation of TAMs was abrogated in CCR5 knockout mice compared to wild type 




Figure 6.24: Distribution of tumor-infiltrating myeloid cells and Tregs upon chemokine injection 
C57BL/6 mice (n=3) were subcutaneously injected with 10
6
 RMA-S cells and intra-tumorally with 1 µg recombinant 
CCL3, CCL4, CCL5 or PBS every third day. A) Percentage of myeloid cells was analyzed on day 13 after tumor cell 
inoculation. B) Percentage of Tregs, CD4/Treg and CD8/Treg ratios were assessed on day 13 after tumor cell 
inoculation. Values represent the mean ± SD of each group. *P < 0.05 






















6.6 Manipulation of MDSCs in vivo 
 
Previously, we showed that tumor-infiltrating MO-MDSCs were potent producer of chemokines, 
resulting in increased level of tumor-infiltrating Tregs and reduced CD4/Treg and CD8/Treg ratios. 
To disrupt the CCR5-mediated chemotaxis, we aimed to manipulate MO-MDSCs in vivo in order to 
reduce chemokine levels in the tumor and thereby, improve anti-tumor immune responses.  
All-trans retinoic acid (ATRA) is a well known compound, which induces the differentiation of 
acute promyelocytic leukemia cells and has been successfully used in differentiation induction 
therapy in these patients [141], [142]. Recently, Kusmartsev and colleagues demonstrated that in 
vivo administration of ATRA reduced the amount of MDSCs in tumor-bearing mice by 
differentiating these cells into mature DCs, macrophages and granulocytes [107]. We implanted 
ATRA pellets subcutaneously into tumor-bearing mice to maintain its constant concentration in 
Figure 6.25: Impact of CCR5 deficiency on tumor 
progression 
C57BL/6 wild type and CCR5 deficient mice were 
subcutaneously injected with 10
6
 RMA-S cells A) 
Tumor growth and survival was assessed for 31 





cells as well as CD4/Treg and CD8/Treg ratios 







. Data are 
representative of two experiments. Values 
represent the mean ± SD of each group. *P < 0.05 
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the organism. As a control, mice were implanted with placebo pellets. Treatment with ATRA 
decreased the proportion of PMN- and MO-MDSCs in the tumor. Moreover, the percentage of 
CD11b+F4/80+Gr-1- macrophages was significantly higher in ATRA-treated mice than in mice 
treated with placebo (Figure 6.26A). However, differentiation of MDSCs into macrophages did not 
result in delayed tumor growth (Figure 6.26B). To determine the chemokine levels of CCL3, CCL4 
and CCL5 locally in the tumor tissue after ATRA treatment, tumor lysates were analyzed via ELISA. 
As shown in Figure 6.26C, the overall concentration of CCL3 was significantly reduced after ATRA 



















Figure 6.26: Differentiation of MDSCs in vivo 
C57BL/6 mice (n=18) were subcutaneously injected with 10
6
 RMA-S cells. 11 days (A+B) or 7 days (C) 
after tumor inoculation ATRA (5 mg) or placebo pellets (5 mg) were subcutaneously implanted A) 
Percentage of myeloid subsets was analyzed on day 19 after tumor cell inoculation. B) Tumor growth 
was monitored for 19 days. C) On day 19 tumor lysates were prepared and chemokine production was 
measured using ELISA. Data are representative of two (A, B) and one (C) experiments. Values represent 
the mean ± SD of each group. *P < 0.05. 





Established therapies currently used to treat cancer include surgery, local radiotherapy and 
chemotherapy. However, even when the primary tumor was initially removed, remaining 
micrometastases and cancer stem cells frequently lead to tumor relapse and therapeutic failure. 
Therefore, it became clear that is not sufficient to develop strategies only to eliminate cancer cells 
but also approaches are needed that stimulate anti-tumor immune responses. Dendritic cells 
pulsed with tumor antigens are broadly applied in cancer patients [143]. Adoptive cell therapy 
using autologous tumor-infiltrating T cells was an effective treatment for patients with metastatic 
melanoma [144]. However, a combination of immunotherapy and chemotherapy seems to be the 
most promising approach.  
Researchers over the last decades observed that tumor-infiltrating cells play a dual role in cancer. 
They do not only suppress tumor growth by destroying cancer cells or inhibiting their outgrowth, 
they also promote tumor progression by inducing immune suppression. Understanding how these 
cells affect tumor development and progression is one of the most challenging questions in tumor 
immunology.  
 
7.1 Tumor-infiltrating cells 
 
Lymphocytes like T cells and NK cells were shown to infiltrate tumor tissues in mouse models and 
cancer patients [145], [146]. A high number of tumor-infiltrating lymphocytes is a useful 
prognostic marker in patients with melanoma [147], colorectal cancer [148] and pancreatic 
adenocarcinoma [149] and often correlates with an improved clinical outcome. Immune cells are 
involved in tumor immunosurveillance and elimination. In vivo studies revealed that mice 
deficient in NK or T cell function exhibit a more aggressive tumor growth and metastasis [150], 
[151]. Therefore, strategies resulting in increased infiltration of T cell and NK cells might be a 
promising approach in cancer immunotherapy. 
Certain immune cells were shown to exhibit pro-tumoral features and thereby support tumor 
progression. These cells include Tregs, macrophages and MDSCs. They accumulate in blood and 
spleen, but are also found in the tumor tissue, where they are either induced by the tumor 
microenvironment of recruited by tumor-derived factors [30], [54]. Tregs inhibit anti-tumor 
immunity and promote tumor growth by suppressing host immune responses. Several studies 
reported elevated levels of Tregs in the tumor tissue including breast cancer [152], melanoma 
[153] and lymphoma [154]. Depletion of Tregs in many models led to the induction of anti-tumor 
immune responses [155]. In addition to Tregs, TAMs and MDSCs exhibit pro-tumoral features by 
suppressing effector functions of T cells and NK cells [69], [89]. Blocking their recruitment to the 
tumor tissue and abrogating their suppressive functions are approaches for immunotherapy that 
are currently under investigation (discussed in section 3.4.2 and 3.5.7). Further knowledge about 
the exact nature of immunosuppressive cell populations within the tumor microenvironment, 
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including their phenotypical and functional properties, might improve therapeutic strategies to 
overcome immune suppression within the tumor tissue. 
 
In this study, we phenotypically and functionally characterized tumor-infiltrating MDSC 
subpopulations from RMA-S lymphoma. We showed that the monocytic subset within the tumor 
tissue exhibited at least three distinct features which might support tumor progression:  
(i) increased expression of the suppressive factors arginase-1 and iNOS, whose activities are 
connected with T cell suppression (ii) pro-inflammatory phenotype distinguished by elevated 
levels of CD14, TLR-4 and Dectin-2 that are known to promote tumor progression and (iii) 
production of the chemokines CCL3, CCL4 and CCL5 at the tumor site, which might support the 
recruitment of pro-tumoral effector cells. 
 
7.2 Tumor-infiltrating MDSC subpopulations 
 
Tumors use a variety of suppressive strategies to escape from immune responses. One of the 
common features of tumor progression is the dysregulation of myelopoiesis and the induction 
and the expansion of MDSCs. It is well established that MDSCs accumulate in bone marrow, blood 
and spleen of tumor-bearing mice and cancer patients and suppress T cell function [115], [156]. 
They comprise a heterogeneous population consisting of monocytes, macrophages, granulocytes 
and dendritic cells. Due to the heterogeneity of MDSCs no common marker has been described so 
far [157]. Movahedi et al. demonstrated that in mice splenic Gr-1+CD11b+MDSCs consisted of a 
Ly6G+SSChigh polymorphonuclear (PMN) and a Ly6G-SSClow mononuclear (MO) fraction. MO-MDSCs 
express the macrophage marker F4/80 that was absent on the PMN-MDSC subset [64]. Since most 
studies had been focused on MDSCs that accumulate in spleen of different tumor models, we 
characterized the phenotype of discrete tumor-infiltrating MDSC subsets from the TAP2-deficient 
RMA-S lymphoma.  
We demonstrated that MDSCs accumulated in blood, spleen and tumors. In concordance with the 
findings of Movahedi et al., two major subsets of tumor-infiltrating MDSCs from RMA-S were 
identified [64]. Differential expression of Ly6G and Ly6C as well as different morphologies defined 
these two subsets as mononuclear (MO) and polymorphonuclear (PMN) MDSCs. Our experiments, 
addressing dynamics of these two subpopulations revealed a high turnover rate of MO-MDSCs in 
bone marrow, spleen and tumor and only low proliferation levels in blood (Figure 6.4). We 
assume that this population migrates from bone marrow through the blood stream and infiltrates 
into peripheral organs such as spleen and tumor, where they further proliferate. In our 
preliminary experiment, PMN-MDSC expanded neither in bone marrow or blood, nor in spleen 
and tumors, suggesting that these cells arise in situ from precursors other than Gr-1+CD11b+F4/80- 
(Figure 6.4). 
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Our further characterizations by flow cytometry described MO-MDSCs by high expression of 
CD124 and CD115 and high levels of the adhesion molecules CD54, CD43 and CD31. CD54 is a 
glycoprotein that can be induced by IL-1 and TNF-α. It binds the integrins Mac-1 and LFA-1, which 
are expressed by activated leukocytes [158], and plays an important role in intercellular adhesion. 
Moreover, MO-MDSC exhibited high expression of several molecules involved in antigen 
presentation. Several studies demonstrated the ability of MDSCs to induce antigen-specific T cell 
tolerance in cancer. Upon antigen uptake, MDSCs migrate to peripheral lymphoid organs and 
present these antigens to T cells [159], [160]. Corzo et al. discovered functional differences in  
T cell suppression dependent on the organ infiltrated by MDSCs. MDSCs from peripheral lymphoid 
organs suppressed only antigen-specific CD8+ T cells, whereas tumor-infiltrating suppressed both 
antigen-specific and unspecific T cell activity due to high levels of the transcription factor HIF-1α 
(hypoxia inducible factor 1α) expression in tumor-infiltrating MDSCs [161]. Furthermore, Serafini 
et al. showed that MDSCs took up and processed tumor-associated antigens and thereby, induced 
Treg expansion [87]. In our study, tumor-infiltrating MO-MDSCs expressed high levels of MHC 
class I and II, CD40 and CD86, which increased expressions were confirmed in our microarray 
analysis. These findings suggest that the MO-MDSC subset might interact with certain T cell 
populations in an antigen specific manner. The functional outcome of such an interaction has to 
be investigated in future studies.  
 
7.2.1 Genetic profile of tumor-infiltrating MDSC subsets 
 
In addition to the analysis of surface markers that were previously described to be expressed by 
MDSCs [64], we performed a gene expression profile of blood and tumor-infiltrating MDSC 
subpopulations using whole genome microarrays. Functional classification of differently 
expressed targets between blood and tumor-infiltrating MDSCs revealed several genes, which 
were involved in distinct pathways. Compared to blood MO-MDSC, the tumor-infiltrating subset 
showed upregulations in the MAPK signaling pathway, including surface molecules like CD14 and 
downstream molecules such as Jun, Hras1, Raf1, and Akt2. It is known that triggering of TLR-4, the 
co-receptor of CD14, also activates different inflammatory responses via the transcription factor 
NFκB. Once activated, NFκB leads to the expression of several inflammatory mediators such as 
TNF-α, IL-6 and IL-1β [162], [163]. We found IL-1β to be upregulated at mRNA level, suggesting 
that the above mentioned pathways might be functional in MO-MDSCs and contribute to a pro-
inflammatory environment within the tumor. Ostrand-Rosenberg and colleagues observed that 
MDSC accumulation in spleen and activation was driven by IL-1β [120]. Mice inoculated with 
mammary carcinoma or fibrosarcoma cells secreting IL-1β, developed significantly higher levels of  
Gr-1+CD11b+ MDSCs compared to mice inoculated with non-secreting cells. Our data suggest that 
MDSC might support their own accumulation at the tumor site by producing high levels of pro-
inflammatory cytokines and thereby providing an autocrine feedback loop that sustains the 
accumulation and retention of MDSCs.  
In addition to MAPK signaling, genes involved in T cell receptor signaling were differently 
regulated in tumor-infiltrating MDSCs, including CD3ε, ZAP70, Itk and NFAT. CD3 molecules are 
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known to associate with the T cell receptor and transduce the TCR signal into the cell via 
phosphorylation of ITAMs, which subsequently activates the tyrosine kinase ZAP70 and the 
transcription factor NFAT [164]. Of importance, also CD3δ and CD3γ were upregulated at 
transcriptional level and we confirmed the surface expression of CD3ε on MDSCs by flow 
cytometry (data not shown). It will be important to investigate, to which receptor (other than  
T cell receptor) these CD3 molecules might couple onto MDSCs. At least for CD3ζ, it has been 
shown that it associates with several receptors expressed by NK cells [165], [166]. Whether 
MDSCs express CD3 molecules has not been investigated so far. Further analysis of the CD3 
signaling pathway might reveal new functions of MDSCs and their contribution to the tumor 
progression. 
The most striking observation of gene expression profiling was that the tumor-infiltrating  
MO-MDSC subset showed pronounced differences when compared to all other subsets including 
blood of naïve and tumor-bearing mice. 411 genes were found to be explicitly upregulated only in 
tumor-infiltrating MO-MDSCs. Briefly, three main features were further investigated. First,  
MO-MDSCs within the tumor displayed high levels of the suppressive enzyme arginase-1. Second, 
we observed an upregulation of several genes involved in pro-inflammatory signaling. And the 
third group comprised several chemokines, which were highly upregulated only in tumor-
infiltrating MO-MDSCs. These findings will be discussed in the following sections. 
 
7.2.2 Suppressive factors and their influence on immune cells 
 
The role of MDSCs as suppressor cells that downregulate antitumor immunity has been well 
established by several studies. They are potent inhibitors of both antigen-specific and non-specific 
T cells activation. Both T cells subsets, CD4+ and CD8+ T cells, are defined as targets of suppression 
that requires cell-cell contact [118]. In vivo treatment of tumor-bearing mice with 
chemotherapeutic drugs, antibodies to Gr-1 or retinoic acid reduced the amount of MDSCs, 
reversed T cell suppression and delayed tumor growth [111], [167]. One of the aims of our project 
was to determine the interaction of tumor-infiltrating MDSC subsets with T cells. Microarray 
analysis revealed that the expression of arginase-1 was significantly upregulated in MO-MDSCs 
within the tumor compared to blood, and its enzymatic activity was confirmed at protein level 
(Figure 6.8). In addition, the same subset displayed high iNOS activity, which was increased by 
three fold compared to the MO-MDSC subset from blood (Figure 6.9A). However, our present 
study showed that tumor-infiltrating MDSC subsets did not exert T cell suppression but rather 
supported their proliferation (Figure 6.18). At the same time, we were unable to reproduce the 
previous results of Nausch et al. demonstrating that splenic MO-MDSCs from RMA-S tumor-
bearing mice diminished T cell proliferation [91]. In our study, MDSCs isolated from blood or 
spleen from RMA-S tumor bearing mice had no effect on T cell activation or moderately enhanced 
T cell proliferation. Similar results were repeatedly observed and the effect was dose-dependent. 
Several possibilities have been considered and are currently under investigation: 
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(i) Several studies demonstrated that both human and murine MDSCs induced the development, 
recruitment and expansion of Tregs. Dependent on the tumor type, Treg induction was either 
TGF-β- and IL-10-dependent [68], mediated via arginase-1 [87] or driven by CD40 expression on 
MDSCs [103]. In our study, high arginase-1 activity as well as expression of CD40 was detected in 
tumor-infiltrating MO-MDSCs. It is therefore possible that tumor-infiltrating MO-MDSCs support 
the proliferation of Tregs in the tumor tissue and use the same mechanisms to support T cell 
proliferation in our in vitro system. The effects observed with splenic and blood MDSCs were 
much less pronounced. Discrepancy with the previous report might be the consequence of 
differential induction of Tregs in MDSC co-culture experiments. Further experiments need to be 
performed to analyze whether Treg induction and expansion play a role in T cell suppression 
mediated by splenic and tumor-infiltrating MDSC subsets. 
(ii) An alternative possibility is that MDSCs, once infiltrated into the tumor tissue, change their 
suppressive potential due to the tumor microenvironment. The study from Haverkamp et al. 
analyzed the influence of tissue-specific inflammatory response on MDSC-mediated T cell 
suppression [168]. These data demonstrated that the regulation of T cell function by MDSCs was 
restricted in vivo to the site of ongoing immune responses, while MDSCs from peripheral tissues 
were not suppressive without activation of iNOS by exposure to IFN-γ. The main producers of  
IFN-γ are NK cells, activated T cells and macrophages polarized towards M1 phenotype. It is, 
however, well established that tumor microenvironment negatively affects the effector functions 
of all three cell subsets, including IFN-γ secretion [30]. As discussed in section 4.3, TAMs resemble 
the M2 phenotype, which mainly produces IL-10 and IL-1 receptor antagonists while inhibiting 
pro-inflammatory responses. It is therefore possible that MDSCs derived from the tumor tissue 
were not exposed to pro-inflammatory stimuli and therefore failed to suppress T cells in vitro. 
Whether the exogenous stimuli might reactivate their suppressive function needs to be further 
analyzed. Of note, Gabrilovich and colleagues reported an increased suppressive potential of 
tumor-infiltrating MDSCs in the EL-4 lymphoma tumor generated as ascites [161]. It is important 
to analyze whether the inflammatory microenvironment of ascites might be different compared 
to established solid tumor and thus favor the MDSC suppressive phenotype.  
(iii) Ribechini et al. reported that the α-Gr-1 mAb transmitted signals via STAT-1, STAT-3 and  
STAT-5 into bone marrow cells in vitro and remained attached to the cell surface for at least four 
days [110]. In addition, α-Gr-1 mAb injection in vivo induced signals leading to myelopoiesis and 
reduced MDSC suppressive activity. For the isolation of MDSCs from tumor bearing mice we have 
used the α-Gr-1 mAb and the antibody was still detectable on the surface of MDSCs after co-
culture with T cells. Therefore, it is possible that the α-Gr-1 mAb induced differentiation of 
isolated tumor-infiltrating MDSCs in vitro and subsequently abrogate the suppressive potential of 
these cells. However, an alternative isolation procedure without Gr-1 engagement led to similar 
results, thus excluding its signaling effect on MDSCs. 
  
Eva Schlecker  DISCUSSION 
 
81 
In our previous report, we described that MO-MDSCs from blood expressed Rae-1 and induced 
IFN-γ release by NK cells. IFN-γ production in co-culture of MO-MDSCs and NK cells was partially 
blocked by addition of an α-NKG2D mAb [91]. As in blood MO-MDSCs, we detected high levels of 
the NKG2D ligand Rae-1, which was exclusively expressed on the monocytic subpopulation. In 
addition, we showed that tumor-infiltrating MO-MDSCs also induced IFN-γ release by NK cells. 
Due to high expression of Rae-1 on the monocytic population in the tumor, an interaction with 
NKG2D on NK cells might also lead to IFN-γ induction. Rae-1/NKG2D interaction may delineate a 
mechanism by which MO-MDSCs and NK cells directly interact. It has been shown that IFN-γ is 
essential for activating the suppressive function of MDSCs and blocking of IFN-γ reversed the  
T cell suppression mediated by MO-MDSCs [64]. Therefore, elevated IFN-γ production by NK cells 
in co-culture with MO-MDSCs might further increase the suppressive potential on T cell 
responses. 
Whether human MDSCs express NKG2D ligands, has not been reported so far. Compared to 
murine MDSCs, MDSCs in humans are still poorly defined. Due to the lack of a Gr-1 homologue, 
several combinations of surface molecules have been used to describe MDSCs in cancer patients. 
In melanoma patients, the monocytic fraction, which express CD14+CD11b+HLA-DR-CD124+, was 
identified to mediate immune suppression [72],[75]. Nowbakht et al. reported that CD14+ 
immature human myeloid cells expressed NKG2D ligands [169]. Since MDSCs are comprised of 
different myeloid cell populations, MDSCs from melanoma patients might express potential 
ligands for NKG2D, suggesting a possibility for MDSC – NK cell cross-talk also in humans.  
In addition to NK cells, CD8+ T cells and γδ T cells express the NKG2D receptor [170]. Therefore, 
interactions with Rae-1 expressed on MO-MDSCs might not be restricted to NK cells. Future 
studies with NKG2D expressing immune cells will further investigate the influence of MDSCs on 
activation on distinct immune responses. Vice versa, MO-MDSCs might also suppress immune 
responses via Rae-1. Shedding of NKG2D ligands as soluble molecules has been studied 
extensively. Tumor cells evade NKG2D surveillance by releasing matrix metalloproteinases 
(MMPs) that cleave NKG2D ligands from the cell surface resulting in downmodulation of the 
NKG2D receptor on NK cells and inhibition of anti-tumor immune responses. It has been shown 
that the presence of soluble NKG2D ligands in sera was correlated with compromised immune 
responses and accelerated tumor progression [171], [172]. Of interest, several members of the 
MMP family were upregulated on transcriptional levels in tumor-infiltrating MO-MDSCs. 
Microarray analysis revealed that MMP12, MMP13 and MMP14 were significantly increased (data 
not shown). Therefore, it might be possible that tumor-infiltrating MO-MDSCs suppress immune 
responses via shedding of Rae-1.  
 
7.2.3 Pro-inflammatory phenotype 
 
It is well established that chronic inflammation increases cancer risk and promotes tumor 
progression by causing genetic alterations, fostering neoangiogenesis, altering responses to 
growth signals and inducing cell proliferation accompanied by altered cell recruitment [173]. 
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Recently it became clear, that MDSCs are induced by tumor-secreted and host-secreted 
molecules, many of which are pro-inflammatory factors. In addition to responding to pro-
inflammatory signals, MDSCs contribute to the inflammatory tumor microenvironment by 
secreting pro-inflammatory molecules themselves. By analysis of the transcription profile of 
tumor-infiltrating MO-MDSCs we observed an upregulation of CD14 and TLR-4 as well as potential 
target genes of this pathway (Figure 6.10 and 6.11; Table 6.3). To investigate whether TLR-4 
signaling on MDSCs might contribute to an inflammatory environment, tumor-infiltrating MDSC 
subsets were stimulated with LPS. In addition to high levels of TNF-α and CXCL2 secretion, we 
detected an increased expression of Rae-1 upon stimulation. The exact mechanism leading to the 
upregulation of Rae-1 on MDSCs is unknown. Hamerman et al. reported that several pathogens 
triggered TLR/MyD88 signaling resulting in upregulation of Rae-1 [134].  
Recently, S100A8 and S100A9, two members of the S100 protein family, have been identified as 
important DAMPs (damage-associated molecular pattern) released by activated phagocytes and 
recognized by TLR-4 on monocytes [135]. Several studies confirmed an implication of S100A8/A9 
in tumor biology. In mice, these molecules promote tumor growth as well as metastasis. Mice 
deficient in S100A9 exhibited reduced growth and lacked the accumulation of MDSCs in 
lymphomas and sarcomas. Furthermore, upregulation of S100A8/A9 was observed in splenocytes 
from tumor-bearing mice and was restricted to the Gr-1+ population [81]. Of note, we detected 
increased levels of S100A8/A9 in tumor-infiltrating MDSCs on transcriptional level (data not 
shown). Secretion of S100A8/A9 by MDSCs and binding to TLR-4 on MDSCs indicate a potential 
autocrine effect. Sinha et al. observed that antibody treatment of mice, which block the 
S100A8/A9-binding sites on MDSCs, reduced MDSC recruitment and accumulation as well as 
S100A8/A9 serum levels [82]. However, the relative contribution of extracellular and intracellular 
effects of S100 proteins for MDSC-mediated immune suppression remains elusive. In our studies, 
we discovered that in vitro treatment of tumor-infiltrating MO-MDSCs with S100 proteins induced 
the upregulation of Rae-1, which was more potent than LPS stimulation itself (Figure 6.21). Future 
experiments with TLR-4 deficient MDSCs will clarify whether this induction results from TLR-4 
triggering. Several reports speculated about the existence of more than one S100A8/A9 receptor. 
It has been assumed that the molecules CD36 and RAGE (receptor of advanced glycation end-
products) might be two additional receptors for S100A8/A9 [174-175].  
Whether other TLR-4 ligands are involved in Rae-1 regulation on tumor-infiltrating MO-MDSCs is 
currently under investigation. Hiratsuka et al. identified SAA3 as an endogenous ligand of TLR-4. In 
their study, SAA3 induced chemotaxis of tumor cells and phagocytes and was an important 
downstream target of S100A8/A9. They concluded that S100A8/A9, SAA3 and TLR-4 might 
represent a paracrine positive feedback cascade involved in inflammatory responses [136]. 
Recently, it has been shown that the interaction of high mobility group box 1 protein (HMGB1) 
released from dying tumor cells triggered TLR-4 on DCs, which was required for the cross-
presentation of tumor antigens and the promotion of tumor specific cytotoxic T-cell responses 
[176]. Therefore, HMGB1 might be another TLR-4 ligand leading to Rae-1 induction.  
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In addition to TLR-4 and CD14, another receptor, Dectin-2, involved in inflammatory responses 
was detected on tumor-infiltrating MDSCs. While Dectin-2 was only slightly expressed on blood 
MDSCs, increased levels were displayed on tumor-infiltrating MDSCs from RMA-S tumor-bearing 
mice. Dectin-2 belongs to the Dectin-2 family of C-type lectins, which is comprised of Dectin-2, 
DCIR (dendritic cell immunoreceptor), DCAR (dendritic cell immunoactivating receptor), BDCA-2 
(blood dendritic cell antigen 2), Mincle and Clecsf8. Dectin-2 recognizes zymosan, numerous 
pathogens and mannose and its triggering leads to the activation of the transcription factor NFκB 
and the production of TNF-α [177]. So far, the role of Dectin-2 in the tumor microenvironment is 
unclear. Whether potential ligands of Dectin-2 can be found within the tumor environment will be 
investigated. It is possible that Dectin-2 binds necrotic particles released from tumor cells, which 
has been discovered for its family member Mincle. Yamasaki et al. proposed in their study that 
Mincle recognized SAP130, a soluble protein released from necrotic cells, which resulted in 
cytokine production by macrophages and subsequent neutrophil infiltration into the tissue [178]. 
Of interest, elevated gene expression of Mincle and Clecsf8 was also detected in tumor-infiltrating 
MO-MDSCs in our microarray study (data not shown). 
 
7.2.4 Chemokine-mediated migration 
 
Among different factors that influence tumor progression and metastasis, a major focus in our 
study had been put on chemokines and their receptors. Chemokines play a dual role in cancer: on 
the one hand they possess promalignant potential, on the other hand some chemokines were 
found to act anti-tumorigenic. However, some chemokines exert distinct roles under different 
conditions. The effect of each specific chemokine in tumorigenesis depends to a large extent on 
the tumor type and the tumor model [179], [180], [181].  
In our microarray experiment, we observed that tumor-infiltrating MO-MDSCs exhibited high 
transcript levels of the chemokines CCL3, CCL4, CXCL2, CXCL9, CCL7 and CCL24 compared to the 
other subsets from blood and tumor. Bioplex analysis revealed that most of these changes were 
also present at protein levels (Figure 6.16). The most highly induced chemokines, produced by 
tumor-infiltrating MO-MDSCs were CCL3, CCL4 and CCL5. The latter was additionally included in 
our study, since all three chemokines bind the same receptor, CCR5.  
CCL3 (MIP-1α) and CCL4 (MIP-1β) belong to the macrophage inflammatory protein (MIP) group of 
the CC chemokine subfamily. Despite their structural similarities, CCL3 and CCL4 show diverging 
signaling capacities. CCL3 mRNA is expressed at low levels in resting monocytes and macrophages, 
but increased upon stimulation with LPS, IL-1β or IFN-γ [182], [183]. As previously discussed LPS, 
IL-1β and IFN-γ played an important role in the regulation of MO-MDSCs. Therefore it might be 
possible that these molecules and their signaling pathways are involved in CCL3 regulation. 
Moreover, secretion of CCL3 is known to be enhanced during monocyte-endothelial cell 
interaction, which was ICAM-1-mediated [184]. CCL3 has been found to reversibly inhibit the 
proliferation of certain murine hematopoietic stem cells in vitro as well as in vivo. This effect was 
dependent on the developmental stage of the progenitor cells and the cytokines used as growth 
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stimulators [185]. Like CCL3, CCL4 is produced by monocytes in high amounts upon stimulation 
with LPS or IL-7 [186] and it acts as the chemoattractant mainly for Tregs and monocytes [187]. 
CCL5 (RANTES) attracts T cells, granulocytes, monocytes and macrophages (in particular TAMs: 
see section 3.4) and plays an important role in recruiting leukocytes to inflammatory sites. Tan et 
al. observed that Tregs were recruited by CCL5 in a murine model of pancreatic cancer [140]. In 
melanoma and in papillary thyroid carcinoma, increased CCL5 levels resulted in high infiltration of 
CD8+ T cells [188] and DCs [189], however, their prognostic value remained unclear. In addition to 
its chemoattracting potential, CCL5 also acts as a regulatory molecule by inducing proliferation 
and activation of NK cells to form so called CC chemokine-activated killer cells (CHAK) [190].  
All three chemokines share the chemokine receptor CCR5 as common receptor. It is known that 
CCR5 can be expressed on monocytes, macrophages, activated T cells and NK cells mainly under 
inflammatory conditions [191]. In our RMA-S lymphoma model, CCR5 expression was observed on 
splenic and tumor-infiltrating Tregs as well as on tumor-infiltrating MDSCs. No expression was 
detected on immune cells in the blood (Figure 6.22). Of interest, CD4+ and CD8+ T cells expressed 
CCR5 only when infiltrated into the tumor tissue (data not shown). Therefore, we hypothesized 
that Tregs might be recruited via CCR5 from the periphery to the tumor. To confirm our 
hypothesis, the recombinant chemokines CCL3, CCL4 or CCL5 were intratumorally injected into 
RMA-S tumor-bearing mice. Analysis of the tumor infiltrates revealed higher levels of Tregs when 
CCL4 or CCL5 was injected. Moreover, the ratio of CD4/Treg and CD8/Treg was reduced in 
chemokine-injected mice, suggesting that Tregs might be preferentially recruited to the tumor 
site via CCL4 and CCL5. Repeated injection of chemokines resulted in accelerated tumor growth 
and shortened survival compared to PBS injected mice. Recently, Li et al. reported that Treg 
depletion resulted in complete regression of large established tumors. The depletion induced 
activation of tumor-specific CD8+ T cell and enhanced infiltration of these cells into the tumor 
[192]. Galani et al. demonstrated that Treg depletion in RMA-S tumor bearing mice led to tumor 
rejection, which was dependent on T cells, NK cells and IFN-γ [193]. Therefore, it might be 
possible that in our RMA-S tumor model increased levels of Tregs upon chemokine injection 
suppress anti-tumor immune responses resulting in accelerated tumor growth. Since CCL3 and 
CCL5 are chemokines that bind to several receptors with different affinities (CCL3 binds CCR1 and 
CCR5; CCL5 binds CCR1, CCR3 and CCR5), it has to be considered that other immune cells might be 
additionally recruited via CCR5-independent mechanisms.  
 
7.2.5 The role of CCR5 in tumor progression 
 
The role of CCR5 in cancer remains controversial. While CCR5 expression on tumor epithelia had 
been connected to tumorigenesis [137], some tumor therapies required a functional CCR5 
signaling pathway [138]. Whether our RMA-S cell line express CCR5 has to be analyzed. To 
investigate the role of CCR5 in our model, we took advantage of these mice. Tumor inoculation 
resulted in reduced tumor burden and prolonged survival of CCR5 deficient mice (Figure 6.25A/B), 
which correlated with an increased accumulation of CD4+ and CD8+ T cells compared to wild type 
mice. Of note, tumor-infiltrating CD8+ T cells were shown to play an important role in the control 
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of RMA-S tumor progression (I. Galani, unpublished data). Molon et al. reported that binding of 
CCL3 and CCL4 to CCR5 on T cells reduced the T cell responsiveness to other chemokines [194]. It 
might be possible that due to the absence of CCR5, T cells from knockout mice express a different 
chemokine receptor repertoire or respond differently to other chemokines. Their effector 
potential in anti-tumor immunity remains to be investigated.  
 
Whether human MDSCs secret CCR5 ligands and how these chemokines influence tumorigenesis 
has not been reported. So far, production of CCL3, CCL4 and CCL5 was pinpointed to tumor cells 
of multiple myeloma [195], breast cancer [196], melanoma [197] and gastric cancer [198]. In 
addition to CCR5 expression on human memory T cells and NK cells, CCR5 was also expressed on 
CD34+ hematopoietic progenitor cells [199]. Since human MDSCs are comprised of different 
myeloid progenitors expressing CD34+, it might be interesting to see if human MDSCs express 
CCR5 and if they could be recruited via CCR5 receptors. 
 
7.3 Therapeutic implications 
 
Since no marker is known, which is exclusively expressed on MDSCs, tools to specifically eliminate 
MDSCs are lacking. As discussed in section 3.5.7, several approaches have been made to either 
mature MDSCs by differentiating them into macrophages and dendritic cells, reduce their 
accumulation or inhibit their suppressive function. Many of these strategies were used in 
combination to achieve more effective cancer therapies [118], [200]. In our study, all-trans 
retinoic acid (ATRA) was used to differentiate MDSCs and thereby reduce their potential to 
secrete chemokines. Kusmartsev et al. showed that in vivo administration of ATRA did not only 
reduce the amount of MDSCs but also increase the level of mature cells, including macrophages, 
dendritic cells and granulocytes. Combination of ATRA and DC vaccine significantly prolonged the 
survival rate and reduced tumor growth in the DA3 mouse model of mammary carcinoma [107].  
We implanted ATRA or placebo pellets into RMA-S tumor-bearing mice to assess the effect on 
MDSC differentiation and tumor growth. Eight days after implantation, ATRA efficiently 
differentiated MDSCs into macrophages. However, no therapeutic effect on tumor burden was 
observed (Figure 6.26A/B). This observation might be caused by increased levels of macrophages 
within the tumor tissue detected upon ATRA treatment. The generated macrophages might 
function as tumor-associated macrophages, thereby supporting tumor progression. These findings 
are in concordance with previous studies that ATRA did not directly inhibit the growth of solid 
tumors and combination therapies were necessary [200].  
To investigate the role of chemokine secretion by MDSCs, tumor lysates of ATRA- and placebo-
implanted mice were analyzed. While ATRA treatment significantly reduced the overall secretion 
of CCL3 in the tumor tissue, no effect was seen for CCL4 and CCL5 production. We assume that 
due to differentiation of MDSCs, matured macrophages generated by ATRA treatment, might be 
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an additional producer of these chemokines. Our previous Bioplex analysis showed that TAMs 
were also potential chemokine producers within the tumor (Figure 6.16). Therefore, a 
combination therapy should be considered, to first reduce the amount of MDSCs (like ATRA), and 
second to decrease the level of differentiated macrophages at the tumor site. Using either CpG, 
the ligand for TLR9, which shifts TAMs towards M1 phenotype [57], or clodronate to deplete 
macrophages [201], might be a promising strategy to reduce both MDSC and macrophage levels 
in the tumor tissue. This combination might efficiently decrease the chemokine level and 
subsequently enhance anti-tumor immune responses. 
 
7.4 Concluding remarks 
 
Myeloid-derived suppressor cells play a crucial role in the cellular network that regulates immune 
responses in cancer, inflammation and in other pathological conditions. One of the most 
important hallmarks of MDSCs is the morphological, phenotypic and functional heterogeneity. 
Therefore, the roles of specific MDSC subsets in mediating T cell suppression and the molecular 
mechanisms for their accumulation need to be elucidated. In this study we discovered new 
factors, which might be involved in Treg-mediated T cell suppression. We demonstrated that 
tumor-infiltrating MO-MDSCs secreted high levels of the chemokines CCL3, CCL4 and CCL5 that 
were able to chemoattract CCR5+ regulatory T cells to the tumor site and change the Treg/T cell 
ratio. In summary, we defined a new regulatory role of MDSCs in recruiting Tregs, which might be 
clinically relevant in developing novel immunotherapeutic strategies for cancer patients. 
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μg  Microgram 
μl      Microliter 
μM      Micromolar 
7-AAD      7-Aminoactinomycin D 
ACK      Ammonium chloride potassium phosphate 
Ag      Antigen 
APC      Allophycocyanin 
APC(s)      Antigen presenting cell(s) 
ATRA     all-trans retinoic acid 
BCR      B cell receptor 
BM      Bone marrow 
BrdU     Bromodeoxyuridine 
CD      Cluster of differentiation 
cDNA      complementary DNA 
CFSE      Carboxyfluorescein succinimidyl ester 
Cpm     Counts per minute 
CTL(s)      Cytotoxic T lymphocyte(s) 
Cy      Cyanine 
d      Day(s) 
DC(s)      Dendritic cell(s) 
ddH2O      Double distilled water 
DMEM      Dulbecco/Vogt modified Eagle's minimal essential medium 
DMSO      Dimethylsulfoxide 
DNA      Desoxyribonucleic acid 
EDTA      Ethylenediaminetetraacetic acid 
ELISA      Enzyme-linked immunosorbent assay 
FACS      Fluorescence-activated cell sorting 
FCS      Fetal calf serum 
FITC      Fluorescein-isothiocyanate 
FSC     Forward scatter 
g      Gram(s) 
GM-CSF     Granulocyte-macrophage colony stimulating factor 
h      Hour(s) 
HLA      Human leukocyte antigen 
i.p.      Intraperitoneal 
ICAM      Intercellular adhesion molecule 
iDC      Immature dendritic cells 
IFN      Interferon 
Ig      Immunoglobulin 
IL      Interleukin 
ITAM      Immunoreceptor tyrosine-based activation motif 
ITIM      Immunoreceptor tyrosine-based inhibitory motif 
KEGG      Kyoto Encyclopedia of Genes and Genomes 
KO      Knock out 
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L      Liter 
LPS      Lipopolysaccharide 
M      Molar concentration 
mAb(s)      monoclonal antibody(ies) 
MACS      Magnetic cell sorting 
mDC(s)     Mature dendritic cell(s) 
MDSCs      Myeloid derived suppressor cell(s) 
MFI      Mean fluorescence intensity 
Mφ     Macrophage 
MHC      Major histocompatibility complex 
min      Minute(s) 
mg     Miligram 
ml      Mililitre 
mM      Milimolar 
MMP     Matrix metalloproteinase 
MO     Mononuclear 
mRNA      Messenger RNA 
NF      Nuclear factor 
NFAT      Nuclear factor of activated T cells 
NK      Natural killer 
NKG2      NK group 2 member 
NOS      Nitric oxide syntase 
ORA      Over-representation approach 
PAMP      Pathogen-associated molecular patterns 
PBMC      Peripheral blood mononuclear cells 
PBS      Phosphate buffered saline 
PE      Phycoerythrin 
PerCP-Cy5.5     Peridinin-chlorophyll-protein-complex-cyanine 5.5 
pH      Potential hydrogen 
PI     Propidium iodide 
PI3K      Phosphoinositide 3-kinase 
PMN     Polymorphonuclear 
PRR(s)      Pattern Recognition Receptor(s) 
Rae-1      Retinoic acid early inducible-1 
RAG      Recombination activation gene 
RNA      Ribonucleic acid 
ROS      Reactive oxygen species 
rpm      Rounds per minute 
RPMI      Roswell park memorial institute medium 
RT      Room temperature 
SAM     Statistical analysis of microarrays 
s.c.      Subcutaneous 
SD      Standard deviation 
SSC     Side scatter 
TAP      Transporter associated with antigen processing 
TCR      T cell receptor 
TF      Transcription Factor 
TGF-β      Transforming growth factor β 
Th      T helper 
TLR      Toll-like receptor 
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TNF      Tumor necrosis factor 
Treg      Regulatory T cell 
U      Unit 
ULBP      UL16-binding protein 
UV      Ultraviolet 
VEGF      Vascular endothelial growth factor 
W/O      Without 
WT      Wild type 
ZAP70     zeta-chain-associated protein kinase 70 
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